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FEAR oF CAnCER RECuRREnCE 
Cancer has a high incidence in the Netherlands with more than 100,000 new patients 
treated each year for various diagnoses of cancer [1]. During the last decennia survival 
of cancer patients has improved significantly for reasons such as population screening, 
secondary prevention strategies and improvements in primary and systemic treatment 
options. Due to this improved outcome, the prevalence of cancer patients is also increas-
ing. As a result more patients are faced with the long-term complications of their cancer 
treatment, and the psychological burden of cancer treatment. One of the psychological 
complaints in cancer survivorship is fear of cancer recurrence. Fear of cancer recurrence 
(FCR) has been described as the Sword of Damocles that hangs over patients for the rest 
of their lives [2,3]. Although consensus on defining FCR is lacking, Vickberg’s definition 
is often used: “FCR can be defined as the fear that the cancer will return or progress in the 
same organ or in another part of the body” [4]. Both fear of progression [5] and fear of 
recurrence [4] are used as terms in the scientific literature to describe fears about the 
spread or recurrence of cancer [6]. These descriptions are often handled as comparable 
on a conceptual level [7]  and fit within the definition proposed by Vickberg [4], and are 
therefore referred to as FCR in this introduction. Research has shown that FCR is a com-
mon concern for many cancer patients who have ended their treatment and are in re-
mission [2,8]. Furthermore, it is the most commonly identified unmet psychosocial need 
for help of cancer patients and survivors [9-14] and among the most important reasons 
for consulting a psychologist [15]. FCR is a normal, adequate response to the experience 
of a potentially life-threatening disease. Low to moderate levels of FCR are characterized 
by the ability to reassure oneself after being confronted with triggers. However, some 
patients experience long-lasting and severe FCR. These severe levels of FCR coincide 
with increased functioning impairment, psychological distress, and lower quality of life 
[4,7,8,16-25]. Furthermore, studies show that fearful cancer patients are significantly 
less likely to accept discharge from a cancer center and follow-up with a primary care 
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provider [26], and prefer a longer (life-long) follow-up period than currently offered (5 
years) [27]. FCR is also associated with greater utilization of healthcare resources, such as 
number of medications taken and visits to an emergency room [28], unscheduled visits 
to one’s family physician, and use of complementary and alternative medicines [29], all 
suggesting that FCR is likely to increase costs to the healthcare system [28].    
AssEssMEnt oF FEAR oF CAnCER RECuRREnCE
Recent systematic reviews [8,30] report over 30 FCR measures available to researchers 
and clinicians ranging from purpose-designed longer scales (> 10 items; n=4), brief FCR 
specific scales (2-10 items; n=17), FCR specific subscales within quality of life or psy-
chosocial assessment instruments (n=11), or single items within longer questionnaires 
(n=7) [8]. However, relatively few of the available tools have data on both internal and 
external forms of validity, and only a few scales have comprehensive data available on 
their psychometric properties [30]. Only one study has attempted to establish a clinical 
cut-off score by using a purpose-designed face-to-face semi-structured interview of FCR 
as a gold-standard measure [31]. However, this diagnostic interview has not been vali-
dated. The lack of gold-standard diagnostic criteria limits comparison between studies, 
the capacity to adequately evaluate the criterion validity of different FCR scales, and the 
development of screening tools and FCR-specific interventions [30]. 
CliniCAl lEvEls oF FEAR oF CAnCER RECuRREnCE
Currently, there are no established criteria for defining clinical levels of FCR [30]. Using 
non-validated cut-off scores applied to self-report measures, it is estimated that across 
different cancer sites and assessment tools, half of cancer survivors suffer from moderate 
to severe levels of FCR [8]. Despite the absence of a consensus definition of clinical FCR, 
the literature points to some key characteristics of severe FCR including a perceived risk 
of recurrence that is disproportionate to actual risk, functional impairment resulting from 
FCR, a long duration and greater severity of the problem, and frequent self-examination 
and demands for medical tests for potential signs of recurrence [30]. A recent study in-
vestigated the co-morbidity pattern between FCR and anxiety disorders in patients with 
cancer [6]. The results showed that there is a small group of patients who suffer from 
clinical FCR without simultaneously suffering from an anxiety disorder, but also some 
patients suffer from an anxiety disorder, lacking clinical FCR. In this study, less than 10% 
of the cancer patients were diagnosed with comorbid FCR/anxiety disorder. Post-hoc 
analyses showed that the patients with high FCR were equally burdened by accompa-
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nying mental and somatic symptoms (pathological worry, general anxiety, depressive 
symptoms and somatic complaints) as the group of cancer patients who suffer from 
an anxiety disorder. In addition Simard and Savard [31] developed a semi-structured 
interview on FCR to document psychiatric comorbidity of patients with clinical levels of 
FCR. Their results revealed that cancer survivors with clinical levels of FCR had more cur-
rent psychiatric disorders (60%) than cancer survivors with non-clinical levels. Anxiety 
disorders, especially panic disorder (20%) and generalized anxiety disorder (GAD) (16%), 
were the most frequent comorbid psychiatric disorders sharing characteristics with 
FCR such as the presence of physical symptoms triggering intrusive thoughts associ-
ated with FCR and persistent and excessive worry about health, future, or other real-life 
problems. Therefore, FCR seems to share several underlying mechanisms with anxiety 
disorders [31]. However, the majority of survivors do not appear to experience comorbid 
conditions suggesting that FCR can be a unique problem of cancer survivorship.  
thEoREtiCAl ModEl oF FEAR oF CAnCER RECuRREnCE
As early as 1997, an initial cognitive-behavioral multidimensional formulation of FCR 
was proposed [32], based on Leventhal’s Self-Regulation Model [33]. This self-regulation 
model hypothesizes that stimuli or symptoms generate a subjective representation of a 
somatic problem or health threat and concomitant emotions (e.g. fear/distress), leading 
to coping procedures and appraisals of outcomes. In accordance with this model, Lee-
Jones and colleagues formulated a FCR-specific model in which the patient’s emotional 
reaction (e.g. fear) can result from interpretations of the threat of cancer. These are trig-
gered by the perception of internal cues (e.g. physical symptoms) and/or external cues 
(e.g. media about cancer). Behavioral (e.g. body checking) and physiological responses 
(e.g. somatic symptoms of anxiety) can be the result of and might again influence the 
previous processes. Although this model has had an important contribution to the field 
of FCR, it remains theoretical and is not evidence-based.
dEtERMinAnts oF FEAR oF CAnCER RECuRREnCE
There is a growing body of research on predictors and correlates of FCR, as evidenced by 
the recent publication of three reviews of the literature on this topic [7,8,25]. 
Strong evidence was observed about the relationship between FCR and age indicating 
that younger cancer survivors reported higher FCR. With regard to physical symptoms, 
strong evidence emerged for global side effects, fatigue, pain and body image/appear-
ance complaints suggesting that cancer survivors with more frequent or higher number 
Chapter 1
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of physical symptoms experienced greater FCR. For psychological characteristics, 
strong evidence emerged for positive correlations between FCR and distress, depres-
sion, anxiety and avoidance/intrusion. Negative associations were consistently found 
between FCR and quality of life or functional domains indicating that cancer survivors 
who expressed higher FCR reported lesser global quality of life or wellbeing, emotional/
mental, physical, role, social and cognitive functioning.
Inconclusive evidence with regard to demographic characteristics was found for gen-
der, education, marital status, income, employment and ethnicity. For treatment-related 
variables, the role of stage of disease, having had a recurrence or metastatic disease, 
treatment type, length of treatment, additional treatment (chemotherapy, radiothera-
py), type of surgery and comorbidity remains inconclusive. In terms of psychological 
characteristics inconclusive evidence emerged for anxiety disorders, risk perception, 
social support, self-esteem, and optimism.
Relatively new mechanisms that could play a role in FCR but which are not yet ex-
tensively studied in this context are implicit processes. Research on implicit processes 
provides new ways to understand why people engage in dysfunctional behaviors. To 
date most research on implicit processes has been conducted within the context of the 
anxiety disorders literature. An attentional bias to threat is thought to play a maintain-
ing role in anxiety disorders and positive findings of several innovative attention bias 
modification (ABM) and cognitive bias modification interventions (CBM) which aim to 
reduce attentional bias towards threat and consequently reduce anxiety have been 
published[34-36]. Only one previous study [37] has studied whether attentional bias 
towards threat was linked to FCR and found an attentional bias towards cancer-related 
stimuli, however no difference in high or low FCR. 
CouRsE oF FEAR oF CAnCER RECuRREnCE
The majority of studies conducted on FCR used cross-sectional designs in which the 
relationship between time since diagnosis and severity of FCR gives an indication 
whether FCR increases, decreases or remains stable over time. Only a few studies [5,38] 
found a significant relationship, concluding from these cross-sectional study designs 
that FCR remains stable over time. This finding was confirmed by longitudinal studies 
as shown by the systematic review of Simard and colleagues [8]. Multiple longitudinal 
studies [9,17-19,22,23,39-57] assessed the course of FCR within periods ranging from 
3 months to 6 years. Most studies reported no change over time [5,24,40-51,55], some 
studies showed that FCR decreased after diagnosis or cancer treatment and remained 
stable thereafter [9,19,41,46,52-54,56,57], and only a few studies reported increased FCR 
over time [42,47]. Altogether research up to now suggests that FCR is stable over time.  
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intERvEntions FoR FEAR oF CAnCER RECuRREnCE
To date, there are very few intervention studies that have targeted FCR as a primary or 
secondary outcome in disease-free survivors. One published randomized controlled trial 
has found evidence to support the efficacy of two short-group interventions (cognitive 
behavior group therapy vs. supportive-experiential group therapy) to reduce FoP [58]. 
Compared to the care as usual control group, FoP decreased significantly over time. Pa-
tients with metastases and recurrence of cancer gained most from the interventions. To 
our knowledge four separate large-scale trials of FCR-specific interventions are currently 
conducted in the Netherlands [59], UK [60], Canada [61] and Australia [62]. In these trials 
different approaches are used varying from blended therapy (cognitive behavior therapy 
and e-Health)[59] to individual therapy sessions including emotional expression, behav-
ioral management, cognitive restructuring, relaxation, and caregiver incorporation [60], 
a cognitive-existential group intervention [61], and cognitive behavior therapy with 
components of meta-cognitive therapy and acceptance and commitment therapy (ACT) 
[62]. Furthermore, FCR is addressed as secondary outcome in several intervention stud-
ies targeting improvement of generic emotional outcomes in breast cancer survivors 
with Web-based self-management [63], Mindfulness-Based Stress Reduction [64,65], an 
uncertainty management intervention [66] a communication coaching intervention [67] 
and an emotion regulation intervention [68]. The above mentioned interventions cover 
a range of varying intervention ingredients due to the fact that little is known about 
moderating and mediating factors. 
outlinE oF thE thEsis
This thesis focuses on patients with breast cancer, colorectal cancer and gastro-intestinal 
stromal tumors (GIST). The studies on patients with breast and colorectal cancer provide 
insight into a population with a high incidence in the Netherlands with more than 13,000 
new patients annually for both diseases, whereas GIST are diagnosed infrequently 
(approximately 250-300 new patients annually). The studies on patients and survivors 
with colorectal cancer and GIST provide data on both men and women and therewith 
allow the comparison between these groups. Patients with a GIST were studied because 
of their unique long-lasting treatment in the metastatic phase, and uncertainty with 
regard to the length of remission.   
Since validated measures with appropriate cut-off points were lacking, the research 
described in this dissertation started with the validation of the Cancer Worry Scale (CWS). 
The CWS was originally developed to assess concerns about developing cancer among 
individuals at risk for hereditary cancer. In chapter 2 we investigated whether this 
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questionnaire could function as reliable and valid instrument to differentiate between 
breast cancer survivors with high and low FCR. We hypothesized that with the cut-off 
point established in this study, it was possible to differentiate between high and low 
FCR in subsequent studies. Using the CWS we then aimed to establish the prevalence 
of high FCR.  
In addition to the self-report assessment of FCR in chapter 2, it was investigated if 
high FCR could also be detected in an implicit way. Based on the knowledge that anx-
ious individuals are often faster to detect and process threat-relevant stimuli and are 
more easily distracted from other tasks by these stimuli, an Emotional Stroop Task with 
different sets of stimulus words was performed in chapter 3. It was hypothesized that 
breast cancer survivors would display selective attention towards cancer-related stimuli 
on the Emotional Stroop Task and that women with high FCR would show significant 
longer reaction times than women with low FCR. 
Since feelings of anxiety, stress and uncertainty often occur when cancer patients 
visit the hospital for medical check-ups, we investigated in chapter 4 whether there 
were differences between cancer survivors who were treated with curative intent and 
patients on ongoing continuous treatment regimes who visit the hospital on a regular 
basis for medical check-ups in a sample of patients with GIST. 
A more detailed description of FCR in a retrospective study of a group of colorectal 
cancer survivors is provided in chapter 5 where we were interested in the content of 
FCR and therefore focused on specific triggers, functional impairments and coping 
strategies. In chapter 6, the theoretic model of FCR  was refined and updated with 
recent literature findings and tested. Finally, chapter 7 entails a general discussion of 
the studies presented in this dissertation and discusses implications for future research. 
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AbstRACt
background: In 9-34% of cancer patients, the fear of cancer recurrence becomes so 
overwhelming that it affects quality of life. Clinicians need a brief questionnaire with a 
cut-off point that is able to differentiate between high- and low-fearful survivors. 
objective: This study investigated if the Cancer Worry Scale (CWS) could serve as an 
instrument to detect high levels of fear of recurrence in female breast cancer survivors. 
Methods: One hundred ninety-four female breast cancer patients were assessed up to 
11 years after their primary treatment for cancer. The women returned the question-
naires including the 8-item CWS, 2 items of the Cancer Acceptance Scale, the Checklist 
Individual Strength-Fatigue subscale, and the Cancer Empowerment Questionnaire.
Results: A cut-off score of 13 versus 14 (low: ≤ 13, high: ≥ 14) on the CWS was optimal 
for detecting severe levels of fear of recurrence. A cut-off score of 11 versus 12 (low: ≤ 
11, high: ≥ 12) was optimal for screening. The Cronbach α coefficient of the CWS was 
.87; evidence to support the convergent and divergent validity of the CWS was also 
obtained. The CWS is able to detect high levels of fear of recurrence.
Conclusion: The CWS is a reliable and valid questionnaire to assess fear of recurrence in 
breast cancer survivors. 
implications for Practice: With the CWS it is possible for nurses to screen breast cancer 
survivors for severe levels of fear of cancer recurrence. Thereby, nurses can screen and 
assist survivors in accessing appropriate and available support. 
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intRoduCtion
In recent years, improved methods of early diagnosis and better treatments of breast 
cancer have led to a growing number of survivors. One of the problems cancer survivors 
may need to deal with is fear of cancer recurrence (FCR). Fear of cancer recurrence can be 
defined as the fear or worry that the disease will return or progress in the same organ or 
in another part of the body.1 Even though FCR may be common, some survivors report 
fear that is continuously and excessively elevated and becomes so overwhelming that 
they have difficulties in performing their daily and social activities.2-11 This high level of 
fear is characterized by a perceived risk of recurrence that is often disproportionate to 
the actual risk, functional impairment resulting from FCR, a long duration and greater 
severity of the problem and frequent self-examination and demands for medical tests 
for potential signs of recurrence.12,13 The percentages of cancer survivors experiencing 
high levels of FCR range from 9% to 34%.2-3,14-17 The specific nature and cognitive mecha-
nisms of FCR are unknown. This may be at least partly explained by the complexity and 
the heterogeneity of the phenomenon. The model of Lee-Jones10 hypothesizes that FCR 
is a multidimensional construct. The patient’s emotional reaction (fear) can be the result 
of interpretations and cognitions of the threat of cancer released by perceived internal 
cues (eg, physical symptoms) and/or external cues (eg, follow-up appointments). This 
fear can lead to problematic behaviors, including anxious preoccupations, avoidance, 
and excessive checking, contributing to an increased fear response.10,16 Timely and ad-
equate detection of high levels of FCR will be a first step toward treatment methods for 
FCR in order to improve the well-being of breast cancer patients after treatment. 
To identify women who have high levels of FCR, clinicians need a brief questionnaire 
that imposes little burden on the patient. A recent systematic review of Thewes et al18 
identified 20 relevant multi-item self-report measures to examine FCR. Relatively few 
brief measures were found to have comprehensive validation and reliability data avail-
able. Furthermore, empirically based cutoff scores for these instruments are lacking. 
The aim of this study was to investigate whether the Cancer Worry Scale (CWS) can 
be used as an appropriate instrument to detect FCR in breast cancer survivors. The CWS 
is an 8-item scale used to measure worry about the risk of developing cancer (again) 
and the impact of worry on daily functioning among individuals at risk for hereditary 
cancer.19-21 This scale is short, has acceptable internal consistency, and has been trans-
lated into Dutch. In this study the psychometric qualities of the CWS were estimated in a 
sample of breast cancer survivors by investigating if the CWS achieved a high reliability 
coefficient and convergent and divergent validity. Convergent validity of the CWS was 
estimated by using the concept of FCR and the concept of fatigue, previously found 
to be positively correlated with FCR in cancer patients.22 Divergent validity of the CWS 
was estimated using the concept of psychological empowerment23 that represented 
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participants’ reports of intrapersonal and interpersonal strengths. This concept was 
expected to correlate weakly and negatively to FCR because personal strengths and 
cancer worries are 2 different and opposite constructs. In addition, to determine the 
optimal cutoff point for the CWS as a diagnostic instrument to indicate excessive FCR, a 
receiver operating characteristic (ROC) analysis with 2 items of the Cancer Acceptance 
Scale (CAS) and the CWS was performed. Because FCR has been identified as one of the 
most common psychological challenges for cancer patients, a short questionnaire to 
identify patients who have high levels of FCR would be clinically valuable. Screening 
women for severe levels of FCR is a first step to gaining insight into the mechanisms 
involved, and it could provide nurses with guidance to provide support and assistance 
for these women.
MEthods
Participants
Participants were assessed 1 to 11 years after their primary treatment for breast cancer 
at the Department of Medical Oncology of the Radboud University Medical Centre, 
Nijmegen, in the Netherlands. In order to participate, patients had to be treated with 
curative intent, ended surgery and their primary treatment, and were disease-free. They 
could still be receiving hormonal therapy or trastuzumab. Finally, participants had to be 
able to read and write in Dutch. 
Procedure
Contact information for breast cancer survivors who were eligible to participate was 
obtained by an oncologist (H.W.M.v.L) at the Department of Medical Oncology of the 
Radboud University Medical Centre, Nijmegen, in the Netherlands. An information letter 
about the purpose of the study was mailed to all breast cancer survivors together with 
a booklet including questionnaires on demographic variables and study questionnaires 
measuring FCR, empowerment and fatigue. The breast cancer survivors gave informed 
consent by returning the booklet. Participants who did not want to participate did not 
have to return the booklet. Reasons for not participating in the study were not collected. 
Medical data including cancer stage were extracted by the researcher from the medical 
record.
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instruments 
Cancer Worry Scale (CWS)
The original, English version of the CWS consists of 6 items and has been used in 
research to assess concerns about developing cancer or developing cancer again 
and the impact of these concerns on daily functioning among individuals at risk for 
hereditary cancer.24-28 Cancer worries addressed by this scale were assessed in women 
with abnormal mammograms without breast cancer24, first-degree relatives of ovarian 
cancer patients,25  and women with a family history of breast cancer.26-28 Douma and 
colleagues19 translated the CWS into Dutch and added 2 items to the original CWS that 
address worries about family members and future surgery. With this extended 8-item 
version, studies on cancer worry were conducted among individuals at risk for familial 
adenomatous polyposis,19 Li-Fraumeni syndrome,20 and members of a family with a his-
tory of von Hippel-Lindau disease.21
 The 8 items of the CWS are rated on a 4-point Likert scale ranging from “never” to “al-
most always”. Scores range from 8 to 32. Higher scores indicate more frequent worries 
about cancer. Cronbach α varied from .88 to .89 in samples among individuals at risk for 
hereditary cancer.19-21 
Modified version of the Cancer Acceptance Scale 
The modified version of the CAS, which is derived from the original CAS (7 items; Cron-
bach α = .85), assesses fear of disease recurrence and consists of 2 items: “I worry about 
the cancer returning” and “I am anxious about my health”.
Both items are rated on a 4-point Likert scale ranging from “does not apply to me at all” 
to “completely applies to me.” Scores range from 2 to 8. The 2 items are commonly used 
both in research and in clinical practice at the Department of Medical Psychology as 
well as in the Expert Centre Chronic Fatigue of the Radboud University Medical Centre, 
Nijmegen, for patients experiencing postcancer fatigue.22,29
Cancer Empowerment Questionnaire 
The Cancer Empowerment Questionnaire (CEQ) assesses 4 components of the concept 
‘psychological empowerment’ in cancer patients: personal strength (19 items), social 
support (9 items), community (6 items), and health care (6 items). The 40 items are rated 
on a 5-point Likert scale ranging from “strongly disagree” to “strongly agree”.  Total scores 
can range from 40 to 200. Higher scores indicate stronger feelings of empowerment. 
Cronbach α was .94 in a sample of breast cancer survivors.30
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Checklist Individual Strength, Fatigue Severity Subscale 
Fatigue severity has been measured by the fatigue severity subscale of the Checklist 
Individual Strength, Fatigue Severity Subscale (CIS-Fatigue). The CIS-Fatigue contains 8 
items, and each item is scored on a 7-point Likert scale ranging from “Yes, that is true” to 
“No, that is not true”. A score of 35 or higher on the subscale fatigue severity indicates 
severe feelings of fatigue. A score between 27 and 35 indicates heightened experience 
of fatigue. The CIS showed good reliability (Cronbach α’s varying from .83 to .92) and 
construct validity in the work situation as well as in the clinical setting (chronic fatigue 
syndrome).31-34
statistical Method
Prior to SPSS (version 16.0) data analysis, all relevant data were screened for normality. A 
principal factors method was used to fit the common factor model to the CWS. 
Receiver operating characteristic analysis is a technique that evaluates a test perfor-
mance by providing information relevant to the full range of scores that need to be 
taken into account in making a decision about a threshold for, in this study, indicating 
excessive fear of disease recurrence in this population. A ROC curve (graph of sensitiv-
ity against 1-specificity for CWS against 2 items of the CAS) was plotted. The accuracy 
properties sensitivity, specificity, and positive and negative predictive values were as-
sessed at each cutoff point of the CWS against the 2 items of the CAS, and the area under 
the ROC curve and its 95% confidence interval were examined. A screening instrument 
should identify as many fearful survivors as possible. The proposed cutoff point should 
maximize the proportion of women experiencing FCR scoring positive (sensitivity) and 
maximize the proportion of negative test results corresponding to nonfearful women 
(negative predictive value). To differentiate fearful women from nonfearful women, an 
optimal cut-off point should have high sensitivity and specificity, which maximizes the 
proportion of patients whose test results are accurate.35 The internal consistency for the 
CWS was calculated using Cronbach α.
Validity refers to whether an instrument actually measures what it is supposed to 
measure. Convergent validity involves the extent to which test scores correlate in a 
meaningful way with measures of concepts that are theoretically related. In this study, 
convergent validity of the CWS was measured by calculating Pearson correlation coef-
ficients for the CWS with the CIS-Fatigue and the 2 items of the CAS. A moderate correla-
tion was expected between fatigue and the CWS.23
Divergent validity tests whether concepts that theoretically are supposed to be un-
related are in fact unrelated. Divergent validity was measured by calculating Pearson 
correlation coefficients for the CWS with the CEQ; a small and negative correlation was 
expected. 
27
Validation of the Cancer Worry Scale
Ch
ap
te
r 2
REsults
sample Characteristics 
Three hundred thirteen women received an invitation to participate in the study, of 
whom 207 (66%) returned the questionnaires. Of these, 194 women completely filled 
out the CWS and the 2 items of the CAS, which was required for analyses regarding the 
ROC curve. 
The mean age of the sample was 57.0 (SD, 10.2) years (range, 30-88 years). The mean 
time since surgery was 4.74 (SD 2.3) years (range, 1-11 years). Most of the women (78%) 
were diagnosed with early-stage breast cancer (stages I and II). In 7% of the cases, there 
were no data available on the breast cancer stage. About half of the women (48%) 
underwent surgery combined with chemotherapy and radiotherapy. After primary 
treatment, 68% of the women received hormonal therapy (22% actively at time of data 
collection) and 12% trastuzumab. Forty-three percent of the women had completed 
tertiary education, and about half of the women had paid work outside the home (45%). 
There were no differences between the early-stage breast cancer group and the stage 
III breast cancer group with respect to age (F1, 178 = 2.53, P = .113), time since diagnosis 
(F1, 168 = 0.53, P = .467) and CWS scores (F1, 178 = 1.37, P = .244). The stage III breast cancer 
group was treated more often with chemotherapy and radiotherapy compared to the 
early-stage breast cancer group (χ21 = 4.76, P < .05; and χ21 = 36.21, P < .05, respectively). 
There were small, significant negative correlations between age and CWS scores (r = 
-0.198, P = .006) and time since diagnosis and CWS scores (r = -0.213, P = .004). No cor-
relation was found between cancer stage and CWS scores (r = 0.115, P = .126) (Table 1).
table 1. Demographic and Medical Characteristics of the Study Sample
Breast Cancer Survivors (N=194)
Mean age, y 57.0 SD, 10.2
Education
Primary 10 5%
Secondary 98 51%
Tertiary 83 43%
Employment
Paid work outside home 88 45%
Retired 42 22%
Home management 41 21%
Disablement insurance act 20 10%
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Factor Analysis
The Kaiser-Meyer-Olkin analysis produced by the principal component analysis yielded 
an index of 0.90, and the Bartlett’s test of sphericity was highly significant χ228 = 858, P 
< .001, indicating that the distribution of CWS data met the psychometric criteria for 
exploratory factor analysis. The scree test of eigenvalues plotted against factors sug-
gested a 1-factor solution. All items loaded at 0.40 or greater on the factor and so were 
retained. The factor accounted for a substantial proportion of total item variance (55.2%) 
(Table 2). 
table 1. Demographic and Medical Characteristics of the Study Sample (continued)
Breast Cancer Survivors (N=194)
Sick leave 12 6%
Voluntary work 7 4%
Non-employed 3 2%
Study 2 1%
Years since surgery 4.74 SD, 2.3
breast cancer stage
Stage I 20 11%
Stage II 120 67%
Stage III 40 22%
treatment modalities
Surgery + chemotherapy + radiotherapy 93 48%
Surgery + chemotherapy 68 35%
Surgery + radiotherapy 16 8%
Surgery only 16 8%
table 2. Principal Component Analysis Solution for the Cancer Worry Scale (CWS): Items and Component 
Loadings
CWS Item Component loading
1. How often have you thought about your chances of getting cancer (again)? 0.82
2. Have these thoughts affected your mood? 0.72
3. Have these thoughts interfered with your ability to do daily activities? 0.63
4. How concerned are you about the possibility of getting cancer (again) one day? 0.87
5. How often do you worry about developing cancer (again)? 0.87
6. How much of a problem is this worry? 0.82
7. How often do you worry about the chance of family members developing cancer? 0.42
8. How concerned are you about the possibility that you will ever need surgery (again)? 0.69
29
Validation of the Cancer Worry Scale
Ch
ap
te
r 2
Receiver operating Characteristic Curve
The mean CWS score was 13.4 (SD, 3.9), with a range of 8 to 30. The mean of the 2 items 
of the CAS was 5.0 (SD, 1.4), with a range of 2 to 8. Seventy-eight survivors (40%) were 
diagnosed with FCR using the 2 items of the CAS (CAS > 5). The mean CWS scores were 
significantly higher for women who were fearful (CAS > 5; mean, 16.4) than for those 
women who were not fearful (CAS ≤ 5; mean, 11.4),  t116 = -10.08, P < .001. 
The area under the curve of the ROC analysis showed an 88% (P < .001; confidence 
interval, 0.83-0.93) probability that a randomly selected patient defined as a case by the 
2 items of the CAS scores higher on the CWS than a randomly selected patient defined as 
a noncase. On the basis of the ROC curve, the cutoff score for screening was 11 versus 12 
(low: ≤ 11, high: ≥ 12), with a sensitivity of 96%, a specificity of 56%, a positive predictive 
value of 60%, and a negative predictive value of 96%. With a cutoff point of 11 versus 12, 
39% of the women were identified as being fearful for a recurrence of the disease. The 
optimal cutoff score for differentiating fearful from nonfearful was 13 versus 14 (low: 
≤ 13, high: ≥ 14), with a sensitivity of 77% and a specificity of 81%.  The positive and 
negative predictive values were 73% and 84%, respectively. With a cutoff point of 13 
versus 14, 31% of the women were identified as being fearful for a recurrence of the 
cancer (Table 3, Figure). 
table 3. Accuracy Measures for Cancer Worry Scale (CWS) Scores According to 2 Items of the Cancer Ac-
ceptance Scale for 194 Women Who Survived Breast Cancer
CWS Cut-off 
Score
No. (%) 
≥ Cut-off
Sensitivity, % Specificity, % PPV, % NPV, %
8 vs 9 78 (40) 100 14 44 100
9 vs 10 77 (40) 99 28 48 97
10 vs 11 76 (39) 97 37 51 96
11 vs 12 75 (39) 96 56 60 96
12 vs 13 70 (36) 90 67 65 91
13 vs 14 60 (31) 77 81 73 84
14 vs 15 51 (26) 65 91 84 80
15 vs 16 42 (22) 54 92 82 75
16 vs 17 32 (17) 41 95 84 71
17 vs 18 25 (13) 32 99 96 68
18 vs 19 17 (9) 22 100 100 66
19 vs 20 13 (7) 17 100 100 64
20 vs 21 10 (5) 13 100 100 63
21 vs 22 6 (3) 8 100 100 62
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
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Measure of Agreement
In 80% of the cases, there was agreement between the 2 items of the CAS and the CWS 
concerning the presence or absence of a FCR diagnosis. The degree of agreement was 
analyzed using Cohen’s kappa and was 0.58 (SE, 0.06), a correspondence that is generally 
regarded as satisfactory.36,37
Reliability 
A CWS score was derived by summing the 8 items, with scores ranging from 8 to 30. The 
CWS yielded a high internal consistency reliability coefficient (Cronbach α = .87).
validation Analyses
Convergent validity
Correlation analyses indicated a significant and strong association between the CWS 
and the 2 items of the CAS (r = 0.75, P < 0.001). There was also a significant but moderate 
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Figure 1. Receiver operating characteristic curve of Cancer Worry Scale (CWS) scores against the 2 items of 
the Cancer Acceptance Scale. Labeled points correspond to CWS scores as follows: 1: 8 versus 9; 2: 9 versus 
10; 3: 10 versus 11; 4: 11 versus 12; 5: 12 versus 13; 6: 13 versus 14; 7: 14 versus 15; 8: 15 versus 16; 9: 16 versus 
17; 10: 17 versus 18; 11: 18 versus 19; 12: 19 versus 20; 13: 20 versus 21; 14: 21 versus 22.
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association between the CWS and the CIS-Fatigue (r = 0.34, P < 0.001), indicating a low 
moderate relation38 between feelings of fatigue and FCR.
Divergent validity
Correlation analysis indicated a weak but significant negative association between the 
CWS and the CEQ (r = -0.22, P < 0.001), indicating a weak relation38 between FCR and 
absence of psychological empowerment.
disCussion
Overall, this study supported the reliability and validity of the CWS in a sample of breast 
cancer survivors. Results of the factor analysis revealed that the 1-factor solution could 
be retained and that all 8 items contributed sufficiently to the factor. Furthermore, 
the CWS showed satisfactory discriminatory power relative to the 2 items of the CAS, 
indicating that it is an appropriate screening instrument to identify those women who 
experience high levels of FCR with a cutoff point of 11 versus 12 for screening and a 
cutoff point of 13 versus 14 for differentiating a case from a noncase. 
With regard to the study sample, there was a high response rate in that 66% of the 
women filled in and returned the questionnaires. The mean age of the sample as well 
as the work situation was comparable to other studies that conducted research on 
the breast cancer population in the Netherlands, although the educational level was 
somewhat higher.39,40    
Although this study has a number of advantages, including the high response rate, 
the cutoff points, and the good psychometric properties of the scale, there are some 
limitations. Focusing on female breast cancer survivors rather than a mixed cancer 
population including males prevents generalizing the results to other cancer groups 
and to male cancer survivors. Future research needs to measure these variables and 
define cutoff points of the CWS with male cancer survivors. Because of the variation 
in objective risk of recurrence among different cancer types, FCR is for some survivors 
more real and justified than for others, resulting in higher levels of fear6. It would be 
interesting to measure FCR in different cancer type populations and define cutoff points 
of the CWS for each type. 
The findings in this study can be limited by the heterogeneity of the sample. However, 
with regard to the ranges of age and time since surgery, the correlation with the CWS 
scores was so small that it is unlikely that this would have a substantial impact on the 
results of the ROC analyses. 
In this study the modified version of the CAS was used as standard in the ROC analy-
ses. One could question whether this is the most appropriate measure to use knowing 
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that psychometric properties are available for the original CAS, but not of the modified 
scale. However, the 2 items showed a high intercorrelation (r = 0.58) and are commonly 
used in clinical practice to identify high levels of FCR in cancer survivors experiencing 
postcancer fatigue. Moreover, it is the only available short questionnaire that is trans-
lated into Dutch and therefore the only available questionnaire to use as the standard 
in the ROC analysis. 
The divergent and convergent validity of the CWS was good. The 2 items of the CAS 
were found to measure the same construct of FCR as the CWS. Furthermore, fatigue 
and FCR appeared to be distinct problems that partially overlap. The CEQ measured a 
different construct than the CWS in that there was a low relation between feelings of 
psychological empowerment and FCR. In the future, it would be important to assess 
how the CWS relates to generalized feelings of anxiety and depression. 
Fear of cancer recurrence is considered a common concern during survivorship and 
has been linked to poorer psychological adjustment, increased emotional distress, and 
lower quality of life. Detection is crucial in managing FCR. This study has shown that the 
CWS is an adequate questionnaire to identify women with high levels of FCR and thus 
may have an important contribution in the care of breast cancer survivors.
iMPliCAtions FoR PRACtiCE
Even though fear of recurrence is common, some survivors report more fear than others. 
High levels of FCR can become a significant and chronic problem for cancer survivors. 
Because of the limiting consequences for quality of life, FCR needs to be acknowledged 
as a major topic in psychosocial oncology priority in both research and care. With the 
psychometrically sound CWS, it is possible for nurses to detect high levels of FCR and 
provide the appropriate support to these survivors (eg, psychoeducation or referral to a 
psychosocial expert). 
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AbstRACt
background Anxious people show an attentional bias towards threatening information.
Purpose It was investigated whether an attentional bias exists for cancer-related stimuli 
in breast cancer survivors and if different levels of fear of cancer recurrence would lead 
to different patterns of selective attention. 
Methods Breast cancer survivors with high (n=35) and low (n=32) fear of cancer recur-
rence were compared to 40 healthy female hospital employees. Specificity of attentional 
biases was investigated using a modified Emotional Stroop Task. Self-report measures 
were used to assess depression and anxiety, feelings of fatigue and experienced traumas.
Results Compared to control participants, breast cancer survivors with both high and 
low levels of fear of cancer recurrence showed increased interference for cancer-related 
words, but not for other word types. 
Conclusions The findings suggest a specific attentional bias for cancer-related words in 
breast cancer survivors that is independent of level of fear of cancer recurrence. 
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intRoduCtion
Research on implicit cognitive processes provides new ways to understand why people 
engage in dysfunctional behaviors. It is widely recognized that individuals vulnerable 
to anxiety disorders are characterized by enhanced sensitivity to aversive stimuli [1-
4]. Cognitive theories have proposed that enhanced vulnerability is explained by the 
selective processing of threatening information [5,6]. In anxiety, selective processing 
is defined as an attentional bias towards threatening information. As a result, anxious 
people are often faster to detect and process threat-relevant stimuli and they are more 
easily distracted from other tasks by these stimuli [7]. Due to the attentional bias, threat-
related stimuli become more salient, and as a result, the subject’s estimation of danger 
is enhanced, leading to a subsequent rise of anxiety and emotional disturbances [8,9]. 
Therefore, an attentional bias to threat is thought to play an etiological and maintain-
ing role in anxiety disorders [10]. Studies on interventions in which implicit cognitive 
processes related to anxiety are influenced by cognitive bias modification, reported 
positive findings [11-13]. Fear of cancer recurrence is a type of anxiety that has become 
increasingly important since better treatment options for breast cancer have led to a 
growing number of survivors. Fear of cancer recurrence can be defined as the fear or 
worry that the cancer will return or progress in the same organ or in another part of the 
body [14]. In some survivors, the fear of cancer recurrence is continuous and excessive 
and becomes so overwhelming that it leads to difficulties in daily life [15-24]. In the 
literature, the percentages of cancer survivors experiencing moderate to high levels of 
fear of cancer recurrence range from 22-87% [25]. This suggests that for a substantial 
number of  cancer survivors, this fear becomes a significant problem. 
Attentional biases in anxiety disorders have often been demonstrated with modi-
fied versions of the Emotional Stroop Task in which participants are instructed to name 
the colors of the ink in which valenced words are printed, while trying to ignore the 
meaning of the word. The words vary in their relevance to the participants (e.g., neutral, 
unpleasant). The rationale behind the task is that anxious participants will show delayed 
color-naming times for threat-related words compared to neutral words because the 
threat-related words are particularly distracting and interfere with the color-naming 
process [5]. 
Color-naming interference by threat-related words has frequently been shown in anx-
ious populations. In patients with medical conditions, interference was less frequently 
observed. MacLeod and Hagan studied women at risk for gynecologic cancer with stan-
dardized anxiety and depression questionnaires and an Emotional Stroop Task. After 
several weeks, about half of the sample was found to have cervical cancer and these 
newly diagnosed women filled out an emotional distress questionnaire. Pre-diagnosis 
delayed color naming for subliminally presented words on the Emotional Stroop Task 
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predicted post-diagnosis emotional distress [26]. In a study examining women with and 
without a family history of breast cancer, healthy women who identified a first-degree 
relative with breast cancer reported interference effects for cancer-related stimuli 
[27,28]. Furthermore, Taylor and colleagues investigated the role of attentional bias 
in the development of persistent insomnia by comparing the performance of people 
with cancer who developed acute versus persistent insomnia on an Emotional Stroop 
Task with cancer-related and sleep-related word cues. Only the persistent insomnia 
group demonstrated attentional bias for sleep-related words whereas both groups 
demonstrated attentional bias for cancer-related words [29]. The study of Carpenter and 
colleagues showed that women with deleterious BRCA1/2 mutations evidenced more 
biased cancer-related cognitive processing (more interference on the Emotional Stroop 
Task) than noncarriers, and women with a personal history of breast or ovarian cancer 
evidenced more biased cancer-related cognitive processing (longer response latencies 
on the Emotional Stroop Task) than women with no such history [30]. A study using a 
different paradigm (modified probe position task) to investigate attentional bias related 
to cancer found that breast cancer patients are biased in their attention to verbal stimuli 
specifically related to cancer and that attentional patterns in response to cancer words 
were different for words presented supraliminally (bias to attend to cancer words) versus 
words presented subliminally (oriented away from cancer words) [31]. In the studies de-
scribed above, attentional bias to cancer-related stimuli was found in different samples. 
A relation between attentional bias and fear of cancer recurrence was never the topic 
of interest. Selective attention to threatening external triggers in a patients’ environ-
ment (funeral, television programs about cancer) or internal bodily signs, sensations or 
symptoms (nodule, fever) can lead to enhanced worrying, anxious preoccupations or 
estimation of danger and therewith engagement in dysfunctional behaviors, avoidance, 
and excessive checking, again leading to an increased fear response and emotional dis-
turbances. Measuring implicit cognitive processes in cancer survivors with fear of cancer 
recurrence will advance our understanding of the development and maintenance of 
fear of cancer recurrence and can provide new routes for interventions (e.g., Cognitive 
Bias Modification) to reduce this fear.  
The aim of the present study was to investigate whether breast cancer patients with 
fear of cancer recurrence show an attentional bias towards cancer-related stimuli. Breast 
cancer patients experiencing high levels of fear of cancer recurrence were compared 
to breast cancer patients experiencing low levels of fear of cancer recurrence and to 
female hospital employees on an Emotional Stroop Task with cancer-related words (e.g., 
“chemo”). It was hypothesized that patients show most color-naming interference to 
threatening stimuli in their own domain of threat, meaning that they would display 
longer color-naming times when presented with cancer words, indicating cognitive 
interference when confronted with these stimuli. Furthermore, it was hypothesized that 
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the highest interference in breast cancer survivors would occur for those with high lev-
els of fear of cancer recurrence. In addition, feelings of anxiety and depression, levels of 
fatigue, and traumatic experiences were assessed in order to demonstrate the integrity 
of the groups.   
MEthods
Participants
Three groups were included in the present study: Female breast cancer survivors with 
high levels of fear of cancer recurrence, female breast cancer survivors with low levels 
of fear of cancer recurrence, and a control group consisting of healthy female hospital 
employees with no history of cancer. Female hospital employees were selected because 
these women are expected to be as familiar with the hospital-related stimuli as the breast 
cancer survivors are, while they do not necessarily experience them as threatening. The 
breast cancer survivors were assessed 1-10 years after their primary treatment for breast 
cancer. To be eligible, the women had to be treated with curative intent, ended their 
primary treatment and were disease-free at the time of participation. Although they had 
finished surgery and their primary treatment, they could still receive hormonal therapy 
or a specific antibody (trastuzumab). In addition, all participants had to be able to read, 
write, and speak Dutch fluently.
Contact data of 313 breast cancer survivors were obtained by an oncologist (HvL) 
at the Department of Medical Oncology of the Radboud University Medical Center, 
Nijmegen, in the Netherlands. A questionnaire booklet including a modified version of 
the Cancer Acceptance Scale and the Cancer Worry Scale as measurements for fear of 
cancer recurrence was sent by mail. The breast cancer survivors were asked to return the 
questionnaire and give their approval to provide more information about this study. Two 
hundred and seven women (66%) returned the questionnaires. Of these, 131 women 
gave their approval of which 55 were highly fearful for a cancer recurrence (Cancer Ac-
ceptance Scale>5), 46 had low levels of fear of cancer recurrence (Cancer Acceptance 
Scale<5), and 30 women experienced moderate levels of fear of cancer recurrence (Can-
cer Acceptance Scale=5). Parallel to the study, the Cancer Worry Scale was validated with 
a diagnostic cutoff point (low ≤13; high ≥ 14) [32]. Women who scored high or low on 
both the Cancer Acceptance Scale and Cancer Worry Scale were included in the study. 
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instruments
Stroop Task
A list of 15 cancer-related stimulus words was derived along with four additional lists 
of words. The latter were needed for purpose of comparison, to confirm specificity of 
effects. They consisted of 15 hospital-related words to assess non-cancer disease-
related information processing; 15 non-disease-related negative words to assess 
general threat-related information processing; 15 positive words to assess processing 
of non-threatening, but emotionally valenced information; and 15 neutral words to as-
sess the mental challenge of color-naming in the absence of threatening or otherwise 
emotionally valenced stimuli.
The positive, negative, and neutral words were generated from lists appearing in 
previous studies using similar Stroop tasks [27,33]. The list of hospital-related words 
was generated by a group of researchers in the medical field, clinical psychologists, and 
medical psychologists. To generate a pool of potential stimulus items for the cancer con-
dition, this group was asked to write down all of the words they thought were related 
to breast cancer and cancer in general. These words were compared to the word stimuli 
used in the study by Erblich et al. [27] and finally 15 words were selected. All words are 
listed in Table 1. 
All words were in Dutch and single words, and there were no significant differences 
in word length between the five word types. A blocked presentation mode was used 
table 1 Words (translated from Dutch) per category used in the Emotional Stroop Task 
Breast cancer Hospital Negative Positive Neutral Color
Chemo Wheelchair Shame Happiness Hammer Red
Amputation Stretcher Embarrassing Valuable Broom Blue
Radiation Ambulance Solitary Joy Vacuum cleaner Green
Pain Doctor Uncertain Holiday Furniture Yellow
Bald Nurse Humiliating Kind Magazine
Scar Stethoscope Feeling of guilt Love Socket
Metastases Scan Failure Victory Powder
Sick Pills Shyness Cheerful Pencil
Nodule Infusion Antisocial Sunshine Garment
Mammography Medicines Isolation Smile Waste-paper basket
Malignant Syringe Nervous Glad Fork
Tumor X-ray Fail Beach Umbrella
Cancer Waiting room Worthless Friendship Brush
Exhausted Operating room Incompetent Merry Stove
Biopsy Thermometer Incapable Cosy Keys
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and five word tables were created, corresponding to the five word categories. In each 
table, the 15 different words of a single category were presented twice, yielding a total 
of 30 words per table. These 30 words were placed into five columns, each containing six 
words.  The words were presented in the colors green, yellow, red and blue. The distribu-
tion of print colors was the same for each table. The tables were shown on a computer 
screen as colored words presented against a black background with a resolution of 
1,024x768 pixels.
Participants were seated in front of a computer screen and were instructed to name, 
as rapidly and as accurately as possible, the color of the ink in which each stimulus word 
was printed, while ignoring the content of the word. Presentation of each word table was 
started by the experimenter by means of a mouse click. The experimenter also ended 
each table presentation by a mouse click immediately after the last color was named. 
The time between the two mouse clicks was automatically recorded and stored, and 
later analyzed as the main dependent variable. The presentation order of the five tables 
was random, and a practice table including sequences of colored XXXXX strings instead 
of words was presented before the five experimental tables. While the five experimental 
tables were presented, the experimenter was blind to the task conditions on the screen 
and was strategically seated with her back towards the participant. After the five tables 
were presented, a control condition - identical to the practice table - and the incon-
gruent color condition of the original Stroop task (e.g., the word “blue” printed in red 
ink) were displayed as a measure of executive functioning [34]. For each of the tables, 
incorrect responses were recorded as errors by the experimenter on a sheet displaying 
the correct order of the colors.
Questionnaires
Modified version of the Cancer Acceptance Scale 
The modified version of the Cancer Acceptance Scale assesses the patient’s fear of dis-
ease recurrence and consists of two items. Both items are rated on a 4-point Likert scale 
ranging from “Does not apply to me at all” to “completely applies to me”. Scores range 
from 2 to 8 [35,36]. In the present sample, Cronbach’s α = 0.95.
Cancer Worry Scale 
The Cancer Worry Scale consists of eight items and has been used in research to assess 
concerns about developing cancer or developing cancer again and the impact of these 
concerns on daily functioning. The eight items of the Cancer Worry Scale are rated on a 
4-point Likert scale ranging from ‘‘never’’ to ‘‘almost always.’’ Scores range from 8 to 32 
[37]. A diagnostic cut-off score of 14 or higher (sensitivity 77%; specificity 81%) indicates 
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severe feelings of fear of cancer recurrence [32]. In the present sample, Cronbach’s α = 
0.97.
Checklist Individual Strength 
The Checklist Individual Strength measures four aspects of fatigue: subjective fatigue, 
reduced motivation, reduced activity, and reduced concentration. It consists of 20 state-
ments in which the respondent has to indicate on a 7-point Likert scale to what extent 
the particular statement applies to him or her (1 = Yes, that is true; to 7 = No, that is not 
true). Scores range from 20 to 140. The Checklist Individual Strength has good reliability 
[38,39]. In the present sample, Cronbach’s α = 0.93.
Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale is a 14-item self-report screening scale that 
was originally developed to indicate the possible presence of anxiety and depressive 
states in the setting of a medical outpatient clinic. It contains two 7- item scales: one for 
anxiety and one for depression both with a score range of 0 to 21. The Hospital Anxiety 
and Depression Scale have good reliability and validity [40,41]. In the present sample, 
Cronbach’s α = 0.91.
Impact of Event Scale 
The Impact of Event Scale was included to assess the frequency of intrusive and avoid-
ant phenomena after the traumatic experience of cancer. Its 15 items are divided into 
two dimensions: “Intrusion” (7 items) and “Avoidance” (8 items). For every statement, the 
respondent answers on a 4-point scale whether this was present- 0 (not at all), 1(rarely), 
3(sometimes), or 5 (often)-during the past 7 days. The Impact of Event Scale has good 
reliability and validity [42]. In the present sample, Cronbach’s α = 0.95.
Visual Analogue Scale 
A Visual Analogue Scale was used to measure feelings of anxiety. Participants specified 
their current level of anxiety using a Visual Analogue Scale that ranged from 0 (indicat-
ing not anxious at all) to 10 (indicating very anxious).
Procedure
This study was conducted after institutional approval by the Medical Ethical Committee. 
Participants provided written informed consent prior to participation. The assessment 
was administered at the Radboud University Medical Center, Nijmegen at the Depart-
ment of Medical Psychology. Participants first completed the Stroop Task, then they 
completed the questionnaires. At the end of the assessment, participants were debriefed 
and offered a small present in return for their participation.
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Analyses
Repeated-measures ANOVA of the dependent variable (reaction time), with word type 
as within-subjects factor and group as between-subjects factor were performed to 
detect the critical group x word type interactions. Significant interaction effects were 
followed-up with repeated-measures ANOVAs for each group, with planned contrasts 
between the reaction times of the cancer list and the four remaining lists and the control 
condition. 
REsults
demographic and Medical Characteristics
Based on the scores of the Cancer Acceptance Scale, 46 female breast cancer survivors 
with high levels of fear of cancer recurrence and 37 female breast cancer survivors with 
low levels of fear of cancer recurrence participated in the study. Since only women who 
scored high or low on both the Cancer Acceptance Scale and Cancer Worry Scale were 
included in the analyses, data of 35 female breast cancer survivors with high levels of 
fear of cancer recurrence and 32 female breast cancer survivors with low levels of fear 
of cancer recurrence were analyzed. There were no differences between women who 
approved and women who did not approve to enter the study with regard to time since 
surgery t (194) = -1.70, p = 0.09, or disease stage χ2 (2, 193) = 0.18, p = 0.91. However, 
there was a significant difference between the groups with regard to age t (205) = -3.69, 
p < 0.001 indicating that approvers (M = 55.5; SD = 9.8) were significantly younger than 
non-approvers (M = 60.7; SD = 10.0).
Forty female hospital employees participated in this study as a control group. The 
female hospital employee group was significantly younger than the two patient groups, 
F(2,106) = 10.47, p < 0.05, but there were no significant differences between the three 
groups with regard to marital status or children. With regard to the medical data for 
the two breast cancer survivor groups, a significant difference was found for time since 
surgery, indicating that survivors in the low-fearful group were significantly longer in 
remission than the high-fearful group, t (62) = 2.74, p < 0.05. There were no significant 
differences between the groups with regard to stage of disease, χ2 (2, 63) = 0.39, p = 0.48. 
Demographics and medical variables are reported in Table 2.
Emotional stroop task- Attentional bias
Due to the significant age differences between patients and controls, age was included 
as a covariate in the analysis. A 3x5 repeated-measures analysis of covariance (ANCOVA) 
was performed with group as between-subjects factor (high-fearful, low-fearful, hospital 
employees) and word type as within-subjects factor (cancer, hospital, negative, positive, 
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neutral). No significant main effect of age was found, F(1, 103) = 1.86, p = 0.18, partial 
eta2 = 0.02: There was no difference in color-naming times between older and younger 
participants. No interaction effect was found between age and word type. Furthermore, 
the critical word type x group interaction was statistically significant, indicating that the 
patterns of color-naming times differed between the three groups, F(7.4, 379.8) = 2.40, 
p < 0.05, partial eta2 = 0.05. All three groups displayed longer color-naming times for 
cancer words than for the other words. Post-hoc tests revealed that for cancer words, 
the breast cancer survivor groups displayed significantly longer reaction times than the 
control group (p < 0.05). There was no difference between high- and low-fearful survi-
vors (p > 0.05).  Further inspection of the data showed no differences between high- and 
low-fearful survivors (p > 0.05), neither for the cancer words nor for any other word type. 
Reaction time data by word type and group are displayed in Table 3.
original Color-Word stroop task
A 2x3 repeated-measures ANCOVA was conducted with word type (control, incongru-
ent) as within-subjects factor, group (high-fearful, low-fearful, hospital employees) 
as between-subjects factor, and age as a covariate. The results revealed a significant 
interaction between age and word type indicating that older participants had longer 
reaction times on the incongruent color condition than younger participants, F(1,103) 
= 6.22, p < 0.05, partial eta2 = 0.06. No significant group x word type interaction was 
table 2 Demographic and medical characteristics
High fear Low fear Hospital employees
Number (N) 35 32 40
Mean age (SD) 53.9 (10.1) 56.8 (8.5) 48.1 (5.7)
Personal situation
Married/partner 30 (85.7%) 22 (68.8%) 31 (77.5%)
Divorced 0 (0%) 4 (12.5%) 5 (12.5%)
Living alone 3 (8.6%) 4 (12.5%) 4 (10.0%)
Widowed 2 (5.7%) 2 (6.3%) 0 (0%)
Children
Yes 26 (74.3%) 25 (78.1%) 29 (72.5%)
No 9 (25.7%) 7 (21.9%) 11 (27.5%)
Mean years since surgery (SD) 4.4 (2.4) 5.9 (2.4)
Stage of disease at diagnosis
I 3 (8.5%) 3 (9.4%)
II 23 (65.7%) 21 (65.6%)
III 8 (22.9%) 5 (15.6%)
Unknown 1 (2.9%) 3 (9.4%)
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found, indicating that there was no difference between the groups in cognitive speed or 
flexibility, F(2, 103) = 1.16, p > 0.05. 
Error Rates
With regard to the number of errors, the results did not reveal a significant group x word 
type interaction, F(12, 588) = 1.52, p > 0.05. 
Questionnaires
Mean scores and standard deviations are displayed in Table 4. With regard to the cancer-
related questionnaire, the high-fearful breast cancer survivors scored significantly higher 
than the breast cancer survivors with low levels of fear of cancer recurrence. Impact of 
Event Scale Intrusion: F(1,65) = 58.32, p < 0.001; Impact of Event Scale Avoidance: F(1, 
65) = 27.36, p < 0.001. 
For the Checklist Individual Strength, the Visual Analogue Scale, and the Hospital 
Anxiety and Depression Scale, high-fearful breast cancer survivors scored significantly 
higher than both low-fearful breast cancer survivors and the control group. Checklist 
Individual Strength Total F(2, 104) = 17.02,  p < 0.001; Visual Analogue Scale F(2, 104) = 
18.02, p < 0.001; Hospital Anxiety and Depression Scale Total F(2, 104) = 36.57, p < 0.001. 
There were no significant differences between low-fearful breast cancer survivors and 
the control group on these questionnaires. 
disCussion
To the best of our knowledge, this study is the first to focus on attentional biases in breast 
cancer survivors with fear of cancer recurrence. The aim of the present study was to 
table 3. 
Mean reaction times (sec) and standard deviations of the Emotional Stroop Task
High-fearful Low-fearful Control
Emotional Stroop Task
Cancer list 28.6 (6.7) 28.5 (5.3) 23. 5 (4.0)
Hospital list 24.8 (5.5) 23.9 (4.8) 21.5 (3.4)
Negative list 24.5 (5.9) 24.5 (5.5) 21.7 (3.4)
Positive list 24.3 (5.1) 24.2 (4.7) 21.5 (3.4)
Neutral list 23.7 (4.9) 24.4 (4.9) 21.5 (3.4)
Original Stroop Task
Control list 20.8 (3.8) 20.3 (3.7) 19.2 (2.4)
Incongruent color list 40.2 (9.0) 40.5 (9.4) 35.1 (8.0)
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investigate whether breast cancer survivors with high levels of fear of cancer recurrence 
show an attentional bias towards cancer-related words. The results revealed that both 
high-fearful and low-fearful breast cancer survivors showed more interference by can-
cer words than the healthy controls, indicating the role of personal relevance: patients 
show most pronounced color-naming interferences on the specific class of threatening 
stimuli related to their own domains of personal concern [43]. Given that the present 
results did not yield support for the hypothesis that the highest interference in breast 
cancer survivors would occur for those with high levels of fear of cancer recurrence (i.e., 
no difference between high- and low-fearful groups), alternative explanations were 
considered. From the perspective of methodological issues with respect to the content 
of the Emotional Stroop Task the stimulus items were related to cancer in general. To 
find the hypothesized difference between high- and low-fearful survivors, it could be 
important to tailor the stimulus words specific to the fear of cancer recurrence survivors 
experience. It is therefore important to gain more insight in the underlying mechanism 
of this fear to catch the characteristics of this phenomenon in words.  
From the perspective of cognitive models, the event of being diagnosed with and 
treated for breast cancer could have had such an impact that cancer-related stimuli are 
easily activated, resulting in faster detection and processing of this material in both 
high- and low-fearful survivors irrespective of the level of fear of cancer recurrence 
[7].  Furthermore, it is noteworthy to mention that the present study was conducted 
in a hospital setting and it is possible that this setting activated certain fear structures 
because the participants associate the hospital with the negative events of the cancer 
diagnosis, treatment, and stressful follow-up consultations. 
The personal relevance explanation is supported by the specificity of the attentional 
bias with regard to emotional valence and hospital-related generalization. There was no 
generalization of the attentional bias to hospital-related words or emotionally valenced 
words, neither in the highly fearful survivors nor in the other two groups. This finding 
points to the thematic specificity and personal relevance of the attentional bias in that 
it is related to the topic of cancer and not merely based on threat and negative valence. 
table 4 Means and standard deviations per group on the questionnaires
High-fearful Low-fearful Controls
Impact of event scale Intrusion 20.4 (9.3)a 5.2 (6.7)b
Impact of event scale Avoidance 16.7 (9.1)a 5.7 (8.1)b
Checklist individual strength Total 76.2 (26.8)a 54.4 (23.9)b 46.0 (17.6)b
Hospital anxiety and depression scale Total 14.8 (7.8)a 5.1 (4.0)b 5.1 (3.9)b
Visual analogue scale 3.2 (2.8)a 0.8 (1.1)b 0.8 (1.6)b
a vs. b: p < 0.001.
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The findings of the present study contribute to the understanding of attentional 
biases in breast cancer survivors. An attentional bias towards cancer-related words has 
been demonstrated as the color-naming times were significantly longer for these words 
indicating difficulties disengaging attention from them. More research is needed on 
the topic of fear of cancer recurrence and its connection to cognitive processes since 
in this study words related to cancer in general were used. It would be interesting to 
find out which words capture specifically the concept of fear of cancer recurrence and 
to replicate this study to see if it would result in differences in attentional bias between 
high- and low-fearful survivors. Results of the questionnaires revealed significant differ-
ences between the two survivors groups in that the breast cancer survivors with high 
levels of fear of cancer recurrence reported mental and physical complaints whereas 
the breast cancer survivors with low levels of fear of cancer recurrence did not report 
these problems with scores identical to the control group. These results confirm the in-
tegrity of the groups indicating that high-fearful survivors encounter more psychosocial 
problems than low-fearful survivors. Further, survivors in the low-fearful group were 
significant longer in remission than the high-fearful group. Another study also found 
that breast cancer survivors experienced significantly more distress in the first 2 years 
following surgery than in later years [44]. However, although survivors with low levels 
of fear of cancer recurrence report explicitly less psychosocial problems, the findings of 
this study show implicitly an attentional bias toward cancer-related stimuli. It is impor-
tant for cancer support workers to be aware of this discrepancy because this group will 
not appear on a distress screening but still can have negative effects of the cognitive 
interference.  
Methodological issues in the present study merit comment. The small sample size 
could have limited the detection of moderate effects or effects on the various word 
list groups. In addition, women who approved to receive more information about the 
study were significantly younger than women who did not approve. This finding might 
compromise the representativeness of the sample. Also, a significant difference in age 
between the breast cancer survivors and the control group consisting of female hospital 
employees was observed. Within the hospital employee group, the maximum age was 
63 whereas the maximum age of the cancer survivors was 78. Considering options like 
an age-matching procedure would be a valuable recommendation for future research 
as well as the addition of an extra control group since the control group was recruited 
in the context of cancer research which could be related to more concerns about the 
disease in these women compared to women in the general population. Furthermore, 
it should be considered whether the assessment procedures should take place in a 
hospital setting or in a private setting at home. In this study, the hospital setting could 
have influenced the results in that it re-activated the cancer-related fear structures in 
patients, but not in controls.
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In conclusion, this study is the first to investigate Stroop interference in breast cancer 
survivors with fear of cancer recurrence. The main finding of this study is a specific at-
tentional bias towards cancer-related words, found in all survivors, irrespective of their 
fear of cancer recurrence. A significant difference between these two groups on the 
self-report measures, as well as the finding that high-fearful women show more comor-
bid problems, point to the necessity of further research on the topic of fear of cancer 
recurrence and its link to cognitive processes.    
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AbstRACt
background: Gastrointestinal stromal tumors (GIST) are rare and before 2000, patients 
had a dismal prognosis with a median survival of less than a year after tumor metastasis. 
However, the median overall survival has increased to more than five years following the 
introduction of imatinib and other tyrosine kinase inhibitors (TKI). Little is known about 
the psychosocial consequences of treatment of GIST, but this is important because 
patients now are treated and live for longer. This cross-sectional study assessed quality 
of life, distress, and fear of cancer recurrence or progression in patients with GIST. 
Material and Methods: Eighty-six patients with localized or metastatic GIST were asked 
to participate. Patients completed self-report questionnaires including the EORTC-
Quality of Life Questionnaire, Hospital Anxiety and Depression Scale, Impact of Event 
Scale, Cancer Worry Scale, and Fear of Cancer Recurrence Inventory. 
Results: Fifty-four patients (median age 63.3 years) completed the questionnaires, 33 
(61%) of whom were receiving TKI treatment at the time of the study. Overall, the GIST 
patients had a good global quality of life, but 28 patients had high levels of fear of cancer 
recurrence/progression. This high level of fear was not related to patient- or treatment-
related variables. These patients experienced significantly higher levels of psychological 
distress, functional impairments, and difficulty making plans for the future than did 
patients with lower levels of fear. 
Conclusions: More attention should be paid to specific cancer-related problems, such 
as fear of cancer recurrence/progression, in addition to general quality of life issues in 
patients with GIST. 
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intRoduCtion 
Gastrointestinal stromal tumors (GIST) are the most common sarcomas in the gastroin-
testinal tract, with an estimated incidence of 1–2 patients per 100 000 per year [1]. While 
surgical resection is the first choice of curative treatment [2], more than 40% of patients 
with GIST present with metastases or have GIST recurrence or metastases during follow-
up [3]. GIST respond poorly to conventional cytotoxic chemotherapy and radiotherapy, 
with a clinical response rate of less than 5%. The insight of GIST as a mutation driven 
cancer has facilitated the development of targeted kinase inhibitor (TKI) therapies. 
Most GIST express gain-of-function mutations in the tyrosine kinase receptor KIT and/or 
PDGFRA genes [4], and this has revolutionized treatment options and outcomes for GIST 
patients [5]. Imatinib mesylate, a selective TKI, is effective in advanced disease and in the 
adjuvant setting [3,6,7]. Sunitinib has been approved for the second-line treatment of 
metastatic GIST, and more recently regorafenib has been approved for third-line treat-
ment [8,9]. TKI treatment is chronic and orally administered. The median overall survival 
of patients with advanced GIST has increased from less than one year before 2001 to 
more than five years at the present time [10]. This longer survival makes it relevant to 
understand how patients deal with their disease and cope with the ‘Sword of Damocles’ 
of recurrence. In patient populations with increased survival rates, such as GIST patients, 
fear of cancer recurrence/progression (FCR) may be an important and realistic problem. 
This fear manifests itself along a continuum ranging from a normal reaction to a signifi-
cantly clinical one and is reported as a frequent unmet need for supportive care [11]. 
FCR is not only associated with the medical situation, such as cancer itself, with recur-
rence or metastasis, follow-up care, or periodic examinations, but also with psychosocial 
concerns, such as relying on others to perform daily activities, worries about the future 
life, disability, or death [12]. To date, there has been little research on the psychosocial 
consequences of GIST, but a better knowledge of these patients’ FCR would help health 
professionals to support these patients, especially as the availability of systemic therapy 
has increased the survival rate. This study investigates the quality of life and distress of 
patients with GIST. More specifically, it assesses the characteristics of patients who have 
low or high levels of FCR.
MAtERiAl And MEthods
Participants
All patients with localized or metastatic GIST included in the database of the Radboud 
University Medical Center, Nijmegen, the Netherlands, were reviewed for eligibility. 
Eighty-six eligible patients were selected who had been or were currently being treated 
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at the center; they had undergone surgery and/or had received imatinib/sunitinib as 
part of their treatment. All patients were at least 18 years old and had given their written 
informed consent for participation. All were required to be able to read and write in 
Dutch. 
Procedure
The study was approved by the local Medical Ethics Committee. Between June and Oc-
tober 2012, all eligible patients were informed about the study by one of the researchers 
[RT] and provided their informed consent. Thereafter, patients were asked to complete, 
once only, a number of questionnaires (paper or Web-based).
Assessment
Demographic / medical characteristics
Demographic data, including age, gender, marital status, partnership, children, educa-
tion, and employment status, were gathered by self-report. Medical data, including 
disease stage at diagnosis and study participation, risk estimation, active systemic 
treatment at study participation, tumor location, time since initial diagnosis, primary 
treatment, recurrences/metastases, and disease status, were extracted from the patients’ 
medical records by one of the researchers [RT].
Fear of cancer recurrence/progression
The Cancer Worry Scale (CWS) is used in research to assess concerns about developing 
cancer or developing cancer again and the impact of these concerns on daily function-
ing. The instructions for the CWS were adapted to make them suitable for patients who 
were worried about cancer recurrence or progression. The eight items of the CWS are 
rated on a four-point Likert scale ranging from never (1) to almost always (4). Scores 
range from 8 to 32 [13], with a score of 14 or higher being indicative of severe FCR 
(sensitivity 77%; specificity 81%). A cut-off score of 12 or higher can be used to screen 
for FCR [14].
Multidimensional aspects of fear of cancer recurrence/progression
The Fear of Cancer Recurrence Inventory (FCRI) was developed to assess the mul-
tidimensional aspects of FCR. The FCRI consists of seven subscales: triggers, severity, 
psychological distress, coping strategies, functioning impairments, insight, reassurance. 
The ‘triggers’ subscale evaluates the presence of potential stimuli activating fear. The 
‘severity’ subscale measures the presence and severity of intrusive thoughts associated 
with fear. The ‘psychological distress’ and ‘functioning impairments’ subscales evaluate 
the potential consequences of fear. The ‘insight’ subscale measures the level of self-
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criticism about fear intensity. The ‘reassurance’ and ‘coping strategies’ subscales measure 
the variety of coping strategies that can be used to cope with fear. The 42 items are rated 
on a five-point Likert scale ranging from 0 to 4. The FCRI is a reliable and valid self-report 
scale [15]. 
Quality of Life
The EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was developed and 
validated to assess the quality of life of cancer patients. It consists of 30 statements 
related to quality of life on five functional scales (physical, role, cognitive, emotional, 
social), three symptom scales (fatigue, pain, nausea/vomiting), six single symptom 
items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties), 
and a global quality of life scale. Higher scores on the functional scales indicate better 
functioning and quality of life; higher scores on the symptom scales reflect more severe 
symptoms. All scores are transformed linearly and range from 0 to 100 [16]. A difference 
of 5–10 points was considered a small difference, 10–20 points a medium difference, and 
< 20 points a large difference [17].
General Distress
Psychological distress was measured with the Hospital Anxiety and Depression Scale 
(HADS). This questionnaire includes 14 items divided into two subscales: depression 
and anxiety, both seven items. Higher scores indicate more anxiety, depression, and 
psychological distress. The HADS does not contain any somatic items, and so there is 
no confounding by symptoms associated with a physical illness. A total score of 11 or 
higher indicates a mental disorder [18].
Cancer-specific distress
The Impact of Event Scale (IES) was included to assess the frequency of intrusive and 
avoidant phenomena during or after the traumatic experience of cancer. Its 15 items are 
divided into two dimensions: intrusion (7 items) and avoidance (8 items). A total score of 
9–25 reflects moderate adaptation difficulties; a score higher than 26 indicates serious 
adaptation difficulties [19].
data analyses
Prior to SPSS (version 20.0) data analysis, all relevant data were screened for normality. 
Means, frequencies, and descriptives were used to describe the sample. Multivariate 
ANOVAs were performed to assess differences between patients with high or low levels 
of FCR (CWS score ≥14) on several continuous variables. Χ2 analyses were performed to 
assess differences in several categorical variables between the two groups of patients. 
Pearson’s product moment correlations were used to assess relations between con-
Chapter 4
60
tinuous variables. All tests were two-sided with a 5% probability of Type I error (alpha). 
Missing data only occurred in the paper questionnaires and were handled according the 
manual of the specific questionnaire.
REsults
sample characteristics
Eighty-six eligible patients were asked to participate in the study, 55 (64%) of whom 
returned the questionnaires. Of these, 54 patients completed the CWS, which was re-
quired for the analyses. Reasons for non-participation were not collected. There were 
neither differences between responders and non-responders on demographic variables 
[age t (84) = 0.55, p = 0.58; gender Χ2 (1,86) = 0.07, p = 0.79] nor on disease-related 
variables [time since diagnosis t (84) = 0.80, p = 0.43; disease phase at diagnosis Χ2 (1,86) 
= 2.62, p = 0.11; disease phase at study participation Χ2 (1,86) = 0.64, p = 0.42; primary 
treatment option Χ2 (1,85) = 2.64, p = 0.10; risk estimation Χ2 (3,86) = 4.96, p = 0.18; dis-
ease status Χ2 (1,83) = 0.16, p = 0.69). Table 1 shows the patient- and treatment-related 
characteristics of the sample. The median age was 63 (range 21–83) years, and 29 (54%) 
patients were male. Forty-seven patients (87%) were married or had a partner, and 46 
patients (85%) had at least one child. Thirty-two patients (59%) had completed second-
ary education and 23 patients (43%) were retired. The mean time from initial diagnosis 
to study participation was 4.8 (SD = 3.7, range 0.5–17) years. Most primary tumors were 
located in the stomach (n = 20), small intestine (n = 8), or rectum (n = 6). At the time of 
the study, 27 patients (50%) had metastatic GIST: 20 had received surgery and imatinib 
as treatment for metastatic GIST and seven had received imatinib alone. The remaining 
27 patients (50%) were categorized as having local GIST: 24 patients had undergone 
surgery and seven had received imatinib postoperatively. Three patients with local GIST 
received imatinib in a preoperative setting. At the time of study participation, 29 (54%) 
patients had no evidence of disease and 25 (46%) were alive with disease. 
Quality of life and distress
Table 2 shows the mean (±SD) scores for the quality of life and distress questionnaires, 
together with the percentage of patients who experienced high FCR, as defined with 
the CWS. Scores on the functional scales of the EORTC QLQ-C30 ranged from 76.9 to 
84.3, indicating that the patients’ quality of life was sufficient overall. Patients reported 
experiencing fatigue, diarrhea, and insomnia. The mean score of 15.1 on the IES indi-
cates that the patients had moderate problems adapting to the traumatic experience of 
cancer. When the screening cut-off score of 12 on the CWS was used, 39 patients (72%) 
experienced high levels of FCR; when the diagnostic cut-off point (≥14) was used,  28 
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table i. Sample characteristics (n = 54)
Age (years) Median = 63.3; range 21-48
Sex: male 29 54%
Marital status
Married/partnership 47 87%
Not in partnership 7 13%
Children: yes 46 85%
Educational level
Primary 2 4%
Secondary 32 59%
Tertiary 20 37%
Employment status
Retired 23 43%
Employed 15 28%
Home management 9 17%
Unemployed/others 16 30%
Time since initial diagnosis (years) Median = 3.9; range = 0.5-17
disease phase at diagnosis
Local tumor 47 87%
Metastatic 7 13%
disease phase at study participation
Local tumor 27 50%
Surgery and/or imatinib 24
Imatinib 3
Metastatic 27 50%
Surgery and imatinib 20
Imatinib 7
Risk estimation at diagnosis
High 32 59%
Intermediate 8 15%
Low 13 24%
Very low 1 2%
location of tumor
Stomach 20 37%
Small intestine 8 15%
Rectum 6 11%
Intra abdominal 4 7%
Liver 3 6%
Duodenum 3 6%
Other 10 19%
Primary treatment
Surgery 43 80%
Imatinib 12 22%
Active TKI treatment at study participation 33 61%
disease status
No evidence of Disease (NED) 32 59%
Alive With Disease (AWD) 22 41%
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(52%) patients experienced high levels of FCR. We adopted a conservative approach and 
defined high versus low levels of fear on the basis of a cut-off score of ≥14. Analysis of 
differences in quality of life and distress between the two groups revealed medium to 
large clinical differences on the subscales role, emotional, cognitive, and social func-
tioning and global health/quality of life, indicating that patients who experienced high 
levels of fear had a worse quality of life. There were medium clinical differences on the 
symptom subscales insomnia, fatigue, pain, dyspnea, and financial difficulties. Patients 
who experienced high FCR reported significantly higher levels of general distress (50% 
vs. 15.4%; p < 0.001) and cancer-specific distress (35.7% vs. 3.8%; p < 0.001) than did 
patients who experienced low FCR (Table 3). 
table 2. Baseline means and standard deviations of the EORTC-QLQ-C30, HADS, IES and % of patients ex-
periencing high FCR (n=54) 
Quality of life Mean (SD)
Physical functioning 84.3 (18.6)
Role functioning 76.9 (28.7)
Emotional functioning 78.4 (25.4)
Cognitive functioning 80.6 (25.6)
Social functioning 80.2 (26.5)
Global health / QoL 77.2 (19.8)
Insomnia 23.5 (30.8)
Fatigue 33.1 (27.3)
Pain 13.0 (21.9)
Dyspnea 16.7 (25.7)
Constipation 18.5 (34.7)
Appetite loss 16.7 (31.6)
Diarrhea 24.7 (29.8)
Nausea, vomiting 9.6 (15.7)
Financial difficulties 13.0 (30.7)
General distress
HADS total 9.3 (7.8)
Cancer-specific distress
IES total 15.1 (16.7)
Fear of Cancer Recurrence/Progression
High FCR (CWS diagnostic cut-off point) n = 28 (52%)
High FCR (CWS screening cut-off point) n = 39 (72%)
CWS, Cancer Worry Scale; EORTC-QLQ-C30, quality of life module; HADS, Hospital Anxiety and Depression 
Scale; IES, Impact of Event Scale 
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Characteristics of fear of cancer recurrence/progression 
Demographic and medical variables
Correlation analyses revealed no association between age and FCR (r = -0.18, p = 0.19) 
or between time since initial diagnosis and FCR (r = 0.12, p = 0.39). χ2 testing also did not 
reveal categorical medical (disease phase, risk estimation, primary treatment, disease 
status, active TKI treatment) or demographic (gender, partner, children) variables to be 
associated with FCR in either patient group. 
Multidimensional aspects of fear of cancer recurrence / progression
MANOVA revealed a significant difference in the variables of the FRCI between patients 
who experienced high and low FCR (F (6,47)= 9.5, p < 0.001; partial eta squared = 0.55). 
Moreover, all dependent variables were significantly different between the two groups 
after Bonferroni correction (Table 4).
table 3. Means and standard deviations of the EORTC-QLQ-C30, HADS and IES (n=54)
Low FCR 
CWS < 14
n = 26
High FCR
CWS ≥ 14
n = 28
EORTC QLQ-C30 Mean (SD) Mean (SD)
Physical functioninga 87.9 (15.8) 80.9 (20.7)
Role functioningb 86.5 (17.7) 67.9 (33.9)
Emotional functioningc 93.3 (9.7) 64.6 (27.7)
Cognitive functioningb 86.5 (22.6) 75.0 (27.4)
Social functioningb 90.4 (15.0) 70.8 (31.3)
Global health / QoLb 83.9 (17.6) 70.8 (19.8)
Insomniab 14.1 (21.4) 32.1 (35.7)
Fatigueb 23.5 (23.6) 42.1 (27.8)
Painb 5.1 (14.7) 20.2 (24.9)
Dyspneab 10.3 (20.6) 22.6 (28.8)
Constipation 17.9 (35.6) 19.0 (34.5)
Appetite lossa 20.5 (36.6) 13.1 (26.2)
Diarrheaa 21.8 (28.2) 27.4 (31.5)
Nausea, vomiting 8.3 (13.5) 10.7 (17.7)
Financial difficultiesb 5.1 (20.4) 20.2 (36.7)
HADS total 5.5 (4.6) 13.0 (8.7) p < 0.001
IES total 6.6 (8.5) 23.1 (19.2) p < 0.001
HADS total > 11 50.0% 15.4% p = 0.007
IES total > 26 35.7% 3.8% p = 0.004
asmall difference 5 - 10 points; bmedium difference 10 - 20 points; clarge difference > 20 points.  EORTC-
QLQ-C30: quality of life module; HADS: Hospital Anxiety and Depression Scale; IES: Impact of Event Scale.
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disCussion
This is the first exploratory study to investigate FCR and one of the very few reporting on 
quality of life and distress in adult patients with GIST. Only one study has focused on the 
general health of pediatric and adult GIST patients, reporting that individuals living with 
GIST experience chronic pain, post-traumatic symptoms and significant anxiety [20]. 
Compared with the quality of life of a reference group of cancer patients with mixed 
diagnoses at different disease stages, as assessed by the EORTC Quality of Life Group 
[21], the results of this study demonstrate that the global quality of life of adult GIST 
patients appears to be good, with GIST patients showing a better quality of life, physical, 
role, emotional, and social functioning than the reference patients, and a comparable 
cognitive functioning. In contrast, the GIST patients reported more problems with diar-
rhea than the reference patients. We found medical variables not to be associated with 
quality of life, and patients had low to moderate levels of distress. Interestingly, quality 
of life differed between patients who experienced high and low FCR, with patients with 
high FCR having a poorer emotional, role, cognitive, and social functioning and report-
ing more problems than the patients with low FCR and the reference cancer population. 
This shift in scores was also observed for the distress measures, indicating that patients 
who experienced high FCR also experienced significantly more general and cancer-
specific distress than did patients who experienced less fear. 
Thus while the overall quality of life seems to be better in GIST patients than in other 
patients with other cancers, a substantial proportion of the GIST patients (52%) reported 
being very fearful about cancer recurrence/progression. This is consistent with a study 
showing that, across different cancer sites and assessment strategies, on average 49% 
of cancer survivors experience moderate to severe FCR [22]. We found that the patients 
who experienced high FCR had more functional impairments in work, daily, and social 
table 4. Means and standard deviations FCRi 
Low FCR High FCR
Questionnaire Mean (sd) Mean (sd) Mean difference 
(95% CI)
p-value
FCRI
Severity** 13.5 (8.0) 27.7 (7.8) -14.2 (-18.5-  -9.9) < 0.001
Psychological distress** 2.5 (2.5) 7.8 (4.2) -5.3 (-7.2- -3.4) < 0.001
Functioning impairments** 2.0 (3.1) 7.7 (6.5) -5.7 (-8.5- -2.9) < 0.001
Triggers** 8.4 (6.6) 17.6 (6.4) -9.3 (-12.8 to -5.7) < 0.001
Insight* 0.3 (0.7) 2.5 (3.2) -2.3 (-3.5 - -1.0) < 0.001
Reassurance* 0.9 (1.4) 2.6 (2.3) -1.7 (-2.8- -0.7) < 0.002
* p < 0.05; **p < 0.001
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activities, and difficulty in making plans for the future than did patients who experi-
enced less FCR. In the systematic review of Koch and Crist [23], younger age was con-
sistently associated with a greater FCR, whereas contradictory findings were reported 
for gender, educational status, marital status, and having children. We found that none 
of the patient characteristics were associated with FCR, and that time since diagnosis 
was not associated with the severity of FCR. There is mixed evidence for an association 
between cancer and treatment-related factors and FCR. As we found no associations 
between patient characteristics or cancer- and treatment-related variables, we looked 
for other explanations for the high proportion of fearful patients. Nowadays, GIST pa-
tients, even those with metastatic disease, can survive for a relatively long time, thanks 
to the availability of different treatment protocols involving TKIs. In the evaluation of this 
long-lasting treatment, patients are frequently evaluated with imaging modalities such 
as computed tomography (CT) scans. In this respect also patients who have been oper-
ated with curative intent have frequent evaluations aimed at the eventual detection of 
relapse of disease. Cancer patients typically feel very anxious and uncertain in the weeks 
before medical check-ups or consultations, worrying about their medical status and the 
results. Afterwards, they emotionally process the information and results given in the 
consultation. Thus each medical consultation is an important event accompanied by 
feelings of distress and uncertainty, especially if there is a high risk of cancer recurrence 
[24]. It is a challenge for both oncology professionals and patients to find a balance 
between the medical need for follow-up and the psychological issues associated with 
these visits. Although the administration of potentially toxic and expensive agents ne-
cessitates frequent evaluation, the frequency of follow-up visits should be established 
bearing in mind the psychological distress these visits cause and the risk of disease 
progression. It might be a case for shared decision making in which the oncology profes-
sional and the patient communicate about the medical priority of frequent follow-up 
investigations and the distress patients experience. Patients can even experience less 
distress when they are informed beforehand about expected effects of certain choices. 
Therewith it can prevent them from automatically attributing normal GIST-related 
physical symptoms or side effects (internal triggers) to progression or recurrence of 
the disease. With regard to external triggers, patients nowadays have access to various 
sources of information. Via the Internet or publications (magazines/newspapers), and 
with the existence of patient associations, many GIST patients have relatively easy ac-
cess to websites containing disease-specific information. While this type of information 
may reassure patients, reducing uncertainty [24,25], it may generate anxiety because 
not all information that is available is relevant or applicable to the individual patient at 
that moment [24]. This is particularly true for GIST patients, given the diversity of medi-
cal variables (high risk vs. low risk, local tumor vs. metastasized, surgery vs. additional 
treatment) in the patient population. Patients would be better discussing their specific 
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case and need for information with their oncologist because he/she can focus on the 
individual situation and estimate the relevance of information to the individual patient 
and tailor the information provided accordingly [24]. 
This study had a number of limitations. The patient sample was rather small (n=54), 
but the response rate was adequate (64%) and statistically and clinically relevant dif-
ferences were found between the patients with high and low FCR. Another limitation 
concerns the use of the CWS to differentiate between these two groups of patients. The 
CWS was validated in breast cancer survivors and it may overestimate or underestimate 
the proportion of patients with GIST who experience FCR. However, another instrument, 
the FCRI, also revealed significant between-group differences on all subscales, indirectly 
validating the use of the CWS.
For future research it would be interesting to study the natural course of fear, tak-
ing into account the many check-up consultations that patients have to attend, and to 
identify predictors of high FCR. As we now have a wider knowledge of tumor-based 
molecular prognostic factors, it is time to focus on individual patient factors, in order to 
support patients living with GIST.
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AbstRACt
Purpose Although long-term colorectal cancer (CRC) survivors generally report a good 
quality of life, fear of cancer recurrence (FCR) remains an important issue. This study 
investigated whether the Cancer Worry Scale (CWS) can detect high FCR, the prevalence, 
and characteristics of FCR in CRC survivors.
Methods Two hundred and eleven patients who had undergone successful CRC surgery 
in the period 2003 - 2010 in the Radboud University Medical Center in the Netherlands 
were asked to participate. All patients were sent an information letter plus question-
naires for collecting information on demographic and medical variables, FCR, distress, 
and quality of life.
Results Seventy-six patients (36%; median age of 67.7 years range 41-88 years) complet-
ed the questionnaires a median of 5.1 years after surgery. A cut-off score of 14 or higher 
on the CWS was optimal to detect high FCR. Twenty-nine patients (38%) experienced 
high levels of FCR, characterized by higher levels of distress, post-traumatic stress symp-
toms and lower quality of life. These individuals particularly reacted to disease-related 
triggers, felt helpless, were worried, and experienced limitations in daily functioning. 
High FCR was not associated with demographic or medical variables.
Conclusion Long after successful CRC surgery, FCR is a serious problem that impairs 
the quality of life for a substantial proportion of patients. With the CWS, it is possible to 
detect high FCR and thereby assist survivors in receiving appropriate care.
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intRoduCtion
Early detection and improved cancer treatment have increased the survival rate of 
colorectal cancer (CRC) over the past decades [1]. This has made it important to pay 
attention to the way survivors deal with chronic or late effects of the disease and its 
treatment.  A number of recent studies have investigated the quality of life (QoL) of 
CRC survivors and have shown that while QoL is reduced after treatment completion, it 
gradually improves over time in the absence of disease recurrence or progression [2-5]. 
While a systematic review found long-term CRC survivors to have good overall QoL [6], 
this does not necessarily mean that these individuals do not experience problems that 
can influence their daily functioning. Not only can CRC survivors have specific physical 
complaints, such as fecal, urinary, or sexual disorders [7], but they might also have an un-
met need for psychosocial help with regard to fear of cancer recurrence (FCR) [8]. FCR can 
be defined as the fear or worry that the disease will return or progress in the same organ 
or in another part of the body [9]. While a normal level of FCR can keep a person alert 
and aware of symptoms [10], high levels of FCR can adversely affect a person’s quality of 
life and social activities [11-14]. Patients may focus obsessively on symptoms [10], which 
can restrict their ability to plan for the future and can lead to numerous unscheduled 
doctor appointments [15,16]. Among the few studies reporting FCR in CRC survivors the 
prevalence of high FCR ranges between 4% and 85% [17-22]. This wide range of percent-
ages high FCR might be attributed to the fact that there is no consensus about what are 
clinically relevant levels of FCR. Furthermore, it might be attributed to the use of various 
instruments to measure FCR for which there are few or no psychometric data or cut-off 
points available [10]. In the research on FCR in CRC patients, some studies did not use 
a FCR specific measure [18,21], whereas others had lacking data on validity [17,19,20]. 
Therewith, interpretation and comparison of percentages high FCR is difficult. Recently, 
a semi-structured interview to identify patients with clinical levels of FCR was developed 
by Simard and Savard [22]. Based on this interview, cutoff scores on the severity subscale 
of the Fear of Cancer Recurrence Inventory (FCRI-SF) were determined. Therewith, it is 
possible to use this scale as gold standard measure for evaluating the criterion validity 
of different FCR scales. The aim of this study is to assess the capacity of the Cancer Worry 
Scale (CWS), validated in a sample of breast cancer survivors [23], as an instrument to 
detect high levels of FCR in a sample of CRC survivors. Furthermore, there has been little 
research on FCR in CRC survivors, its characteristics, and potential risk groups, mainly 
because earlier studies focused on the severity and prevalence of FCR. There is a lack of 
information about what specific triggers make survivors fearful, which strategies they 
use to cope with this fear, and the concrete consequences of FCR in daily life. This study 
focuses on the prevalence and characteristics of FCR in CRC survivors. 
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MEthods 
Participants
In March 2012, participants were recruited from the Department of Surgery, Radboud 
University Medical Center, Nijmegen in the Netherlands. CRC survivors who had been 
treated with curative intent and who were disease-free (no recurrence or metastases) 
1-9 years after surgery were eligible for inclusion. Participants had to be able to read and 
write in Dutch.
Procedure
Documented approval from the local Medical Ethics Committee was obtained prior to 
start of the study. Contact data of CRC survivors were obtained by a surgeon (JW), and 
these individuals were sent a letter describing the purpose of the study and a booklet 
with questionnaires on demographic variables and psychological factors. Participants 
gave their informed consent by returning the booklet. Clinical data were extracted from 
medical records by one of the researchers [SJ].
instruments
Fear of cancer recurrence: severity
The CWS is used in research to assesses concerns about developing cancer or develop-
ing cancer again and the impact of these concerns on daily functioning. The eight items 
of the CWS are rated on a 4-point Likert scale ranging from “Never” to “Almost always”. 
Scores range from 8 to 32 [24]. A diagnostic cut-off score of 14 or higher (sensitivity 77%; 
specificity 81%) was validated for breast cancer survivors and indicates raised levels of 
FCR [23].
Fear of cancer recurrence: multidimensional aspects
The Fear of Cancer Recurrence Inventory (FCRI) was developed to assess the multidimen-
sional aspects of FCR. The FCRI consists of seven subscales: triggers, severity, psychologi-
cal distress, coping strategies, functioning impairments, insight, and reassurance. The 42 
items are rated on a 5-point Likert scale ranging from 0 to 4. The FCRI is a reliable and 
valid self-report scale [25]. 
The subscale Triggers includes eight items, of which seven assess specific situations 
that make one think about the possibility of cancer recurrence; one item assesses to 
what degree these situations are generally avoided. The subscale Severity includes nine 
items assessing the presence, frequency, intensity and duration of thoughts associated 
with FCR, the perceived risk of recurrence, the legitimacy of worrying about cancer re-
currence, and the presence of other unpleasant thoughts or images that come to mind 
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in association with FCR. Recently, data were provided that this subscale may also be 
used as FCRI-short form to screen for clinical levels of FCR. A score of 13 or higher was 
optimal for screening whereas a score of 16 or higher was the optimal diagnostic cut-
off [22]. The subscale Psychological Distress includes four items for emotions frequently 
triggered by thoughts about cancer recurrence. The subscale Coping Strategies assesses 
nine strategies that may be used to cope with FCR including denial, wishful thinking, or 
cognitive avoidance. 
The subscale Functioning Impairments includes six items representing domains that can 
be disturbed by FCR. The subscale Insight includes three items and assesses the extent 
to which patients perceive their fear as excessive or unreasonable. The subscale Reassur-
ance includes three items representing reassurance behaviors specific to FCR.
Distress: cancer-specific
The Impact of Event Scale (IES) was included to assess the frequency of intrusive and 
avoidant phenomena after or during the traumatic experience of cancer. Its 15 items 
(scoring 0,1,3,5) are divided into two dimensions: “Intrusion” (7 items) and “Avoidance” (8 
items). A total score of 9-25 reflects moderate adaptation difficulties; a score higher than 
26 indicates serious adaptation difficulties [26,27].
Distress: general
General distress was measured with the total score of the Hospital Anxiety and Depres-
sion Scale (HADS). This questionnaire includes 14 items divided into two subscales 
(Depression and Anxiety), each with seven items. Higher scores indicate more anxiety, 
depression, and psychological distress. The HADS does not contain any somatic items 
that could be confounded with symptoms associated with a physical illness. A total 
score of 11 or higher indicates high distress [28,29]. 
Quality of life: cancer-related
Quality of life related to CRC was measured with the European Organization for Research 
and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and 
Colorectal Cancer Module (QLQ-CR38). In this study, only scores for the functional scales 
and global health scale were analyzed. Higher scores on functional scales indicate better 
functioning and quality of life. All scores are transformed linearly and range from 0 to 
100 [30,31]. A difference of 5-10 points was considered small; 10-20 points medium, and 
> 20 points large [32]. 
data-analyses
Prior to SPSS (version 20.0) data analysis, all relevant data were screened for normality 
and showed normal distributions. Means and frequencies, were used to describe the 
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sample.  Only complete data for the CWS were analyzed; incomplete data were recorded 
as missing data and excluded from the analyses. Receiving operating characteristics 
(ROC) analysis was conducted to evaluate the performance of the CWS by providing 
information relevant to the full range of scores that need to be taken into account in 
making a threshold for high FCR in a population of CRC survivors. The accuracy proper-
ties sensitivity, specificity, and positive and negative predictive values were assessed at 
each cut-off point of the CWS against the FCRI-SF. Furthermore, the area under the ROC 
curve and its 95% confidence interval were examined. To differentiate high FCR from 
low FCR, an optimal cut-off point should have high sensitivity and specificity, which 
maximizes the proportion of patients whose test results are accurate [33].
Multivariate ANOVAs were performed for continuous variables, to assess differences 
between high and low FCR, based on the cut-off score (low: ≤13; high ≥14). Chi-square 
analyses were performed to assess differences between high and low FCR with regard to 
categorical variables. Pearson product moment correlations and independent sample t 
tests were used to assess relations between continuous variables. 
For a descriptive analysis of the FCRI scores, percentages of responses to the indi-
vidual questions were calculated. In order to reflect the degree of involvement with a 
specific item, varying from small to moderate or large, answers on the subscales Triggers, 
Coping and Reassurance were combined into three answer categories (1) “never/rarel”, 
(2) “sometimes”, (3) “most of the time/all the time”. Answers on the subscales Severity, 
Psychological Distress, Functioning Impairments, and Insight were also divided into 
three answer categories (1) “not at all/a little”, (2) “somewhat”, (3) “a lot/a great deal”.  
REsults
sample characteristics 
Of 211 CRC survivors asked to participate in the study, 80 (38%) returned the question-
naires, and 76 (36%) of whom completed the CWS and were included in the analyses. 
There was no difference between responders and non-responders with regard to gender 
(Χ2 (1, 211) = 0.03, p = 0.87), but non-responders were significantly older (t(209) = 2.0, p 
=0.046). Table 1 shows the demographic and medical characteristics of the responders. 
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RoC analysis
The area under the curve of the ROC analysis showed an 92% (p<0.001; 95%CI=0.85-
0.98) probability that a randomly selected patient defined as a case by the FCRI-SF 
(≥16) scores higher on the CWS than a randomly selected patient defined as a non-case 
(Fig. 1). On the basis of the ROC curve, the optimal cut-off score to differentiate between 
high FCR and low FCR was 13 versus 14 (low ≤13, high ≥14), with a sensitivity of 86% 
and a specificity of 87%. The positive and negative predictive values were 76 and 93% 
respectively (Table 2). 
table 1. Sample characteristics (n = 76)
Age (years) Median 67.3; range = 41-88
Sex: male 40 53%
Marital status
Married/partnership 55 72%
Not in partnership 21 28%
Children: yes 64 84%
Educational level
Primary 3 4%
Secondary 43 57%
Tertiary 25 33%
Other 5 7%
Employment status
Retired 44 58%
Employed 20 26%
Home management 12 16%
Unemployed/others 15 20%
Time since surgery (years) Median 5.1; range = 1.3 – 9.2
location of tumor
Colon 58 76%
Rectum 18 24%
Stoma: yes 13 17%
disease stage
I 13 17%
II 31 41%
III 32 42%
Additional treatment
Chemotherapy: yes 24 32%
Radiotherapy: yes 10 13%
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Fig. 1 Receiver operating characteristics curve of Cancer Worry Scale (CWS) scores against the FCRI-SF ≥16. 
Labeled points correspond to the CWS scores as follows: 1: 8 versus 9; 2: 9 versus 10; 3: 10 versus 11; 4: 11 
versus 12; 5: 12 versus 13; 6: 13 versus 14; 7: 14 versus 15; 8: 15 versus 16; 9: 16 versus 17; 10: 17 versus 18; 
11: 18 versus 19; 12: 20 versus 21; 13: 22 versus 23; 14: 23 versus 24.
table 2. Accuracy measures for CWS scores according to FCRI-SF 
CWS cut-off 
Score
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
8 vs 9 100 28 39 100
9 vs 10 100 45 46 100
10 vs 11 96 61 54 97
11 vs 12 91 72 61 94
12 vs 13 91 81 69 95
13 vs 14 86 87 76 93
14 vs 15 73 89 76 88
15 vs 16 59 92 76 83
16 vs 17 41 100 100 78
17 vs 18 32 100 100 76
18 vs 19 27 100 100 75
20 vs 21 18 100 100 72
22 vs 23 14 100 100 71
23 vs 24 9 100 100 70
NPV negative predictive value, PPV positive predictive value
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Reliability and measure of agreement
The CWS yielded a high internal consistency reliability coefficient, Cronbach α = 0.89. 
The correlation between the CWS and FCRI-SF was r = 0.85. In 87% of the cases, there 
was agreement between the CWS and FCRI-SF concerning the presence or absence of a 
FCR diagnosis reflecting a Cohen’s kappa of 0.71 (SE 0.09).
Prevalence and multidimensional aspects of high FCR
According to the established cut-off point of 14 or higher on the CWS, 29 survivors (38%) 
had high levels of FCR. These individuals experienced significantly more psychological 
table 3. Means and standard deviations of the psychosocial variables
low FCR (n=47)
CWs < 14
high FCR (n=29)
CWs ≥14
EoRtC QlQ-C30 Mean SD Mean SD p value
Global health / QoLc 77.6 (19.1) 56.7 (26.7) p<0.001
Physical functioningb 81.1 (21.9) 68.5 (30.7) p=0.052
Role functioningc 81.7 (24.1) 59.6 (38.1) p=0.004
Emotional functioningc 93.5 (11.3) 72.4 (23.9) p<0.001
Cognitive functioningb 86.5 (18.9) 68.6 (25.1) p=0.001
Social functioningc 93.7 (12.7) 62.8 (38.7) p<0.001
EoRtC QlQ-CR38
Body imagec 91.4 (15.1) 70.4 (32.8) p<0.001
Sexual functioning 23.0 (22.6) 20.4 (19.8) p=0.623
Future perspectivec 88.9 (15.9) 56.8 (27.4) p<0.001
General distress
HADS total 5.5 (5.0) 13.8 (6.9) p<0.001
Cancer-specific distress
IES total 2.8 (6.3) 15.4 (14.6) p=0.001
Intrusion 1.9 (3.9) 8.2 (7.9) p=0.001
Avoidance 0.9 (2.5) 8.0 (7.4) p<0.001
FCRi
Triggers 6.3 (5.6) 15.5 (5.6) p<0.001
Psychological distress 1.9 (2.0) 7.6 (3.5) p<0.001
Functioning impairments 1.1 (2.1) 6.9 (5.3) p<0.001
Insight 0.3 (0.7) 2.1 (2.2) p<0.001
Reassurance 1.1 (2.0) 2.9 (3.1) p=0.005
a small difference 5 - 10 points
b medium difference 10 - 20 points
c large difference > 20 points
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distress, functional impairments, and triggers, showed more insight and sought reassur-
ance more often than the individuals with lower levels of FCR (Table 3).
Relationship between FCR and demographic and medical variables
There were no differences in age (t(74) = 1.58, p = 0.12) or time since surgery (t(74) = 
-0.31, p = 0.76) between survivors with high or low levels of FCR. Chi-square tests showed 
categorical demographic (gender, partnership, children, educational level, employment 
status) and medical variables (location of tumor, stoma, disease stage, additional treat-
ment) not to be associated with FCR.  
Relationship between FCR and distress 
Survivors with high levels of FCR experienced significantly more general distress (t(73) 
= -5.4, p < 0.001) and cancer-specific distress (t(26.5) = -3.9, p = 0.001) characterized by 
post-traumatic stress symptoms including significantly more intrusive  (t(31.3) = -3.8, p = 
0.001) and avoidant (t(27.2) = -4.6, p < 0.001) phenomena after the traumatic experience 
of cancer, than did survivors with low levels of FCR (Table 3).
Relationship between FCR and quality of life 
Compared with low levels of FCR, high levels of FCR were associated with a poorer qual-
ity of life (F(1,66) = 14.1, p <0.001) more impaired role functioning (F(1,66) = 8.7, p = 
0.004), emotional functioning, (F(1,66) = 24.0, p <0.001), cognitive functioning (F(1,66) 
= 11.2, p = 0.001), and social functioning (F(1,66) = 22.9, p <0.001). Moreover, there were 
large (>20 points) clinically relevant differences between survivors with a  high or low 
FCR in global quality of life, role functioning, emotional functioning, and social function-
ing. Survivors with a high FCR had significantly more problems with body image (F(1,70) 
= 13.7, p <0.001) and future perspective (F(1,70) = 39.6, p <0.001) than did survivors with 
a low FCR (Table 3). 
descriptive analyses FCRi 
triggers Medical examinations, feeling sick or physically unwell, and an appointment 
with the doctor or other health professional were the most frequently reported triggers 
for high FCR with 48, 45 and 38% respectively reporting them “most of the time” or “all 
the time”.  
Psychological distress When survivors with high FCR thought about the possibility of 
cancer recurrence, they felt helpless or resign and expressed worry, fear, or anxiety with 
34 and 31% respectively reporting them “most of the time” or “all the time”.
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Functioning impairments High FCR disrupted the ability to make future plans or set life 
goals, relationships with partner/ family, and general quality of life with 18, 17, and 17% 
respectively reporting them “most of the time” or “all the time”.
insight Most survivors with high FCR did not feel that they worried excessively about 
the possibility of cancer recurrence or that other people thought they did with 76 and 
86% respectively reporting this “not at all” or “a little”.  
Reassurance Survivors with high FCR sought reassurance by going to the hospital or 
clinic for an examination or calling their doctor or another health professional with 
21 and 21% respectively reporting them “most of the time” or “all the time”. Few such 
individuals examined themselves to see if they have any physical signs of cancer with 
10.7% reporting this “most of the time” or “all the time”.
Coping strategies Survivors with high FCR coped with this fear by trying to convince 
themselves that everything would be fine or think positively, trying to find a solution, 
and trying to replace this thought with a more pleasant with 39, 36, and 32% respec-
tively reporting them “most of the time” or “all the time”.  
These individuals did not use coping strategies such as praying, meditating or relax-
ation, trying to distract themselves, or trying not think about it with 75, 61 and 57% 
respectively reporting them “never” or “rarely”.  
severity The thought that it is normal to be anxious or worried about the possibility of 
cancer recurrence and the experience of a lot of other unpleasant thoughts or images 
such as death, suffering, consequences for family when thinking about the possibility of 
cancer recurrence were most frequently reported with 61 and 52% respectively report-
ing them “most of the time” or “all the time”.
disCussion
This is one of the few studies to specifically focus on the prevalence and features as-
sociated with FCR in CRC survivors. FCR remains a significant problem for some CRC 
survivors even years after diagnosis, when routine follow-up care has normally ended. 
This study supported the reliability and criterion validity of the CWS in a sample of CRC 
survivors. Furthermore, the CWS showed good discriminatory power relative to the 
FCRI-SF, indicating that it is an appropriate instrument to identify those individuals who 
experience high FCR. Similar to the validated cut-off score in a sample of breast cancer 
survivors [23], a cut-off score of 14 or higher was optimal for differentiating a case from 
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a non-case. With this cut-off point, about one third (38%) of the survivors experienced 
high levels of FCR a median time of 5 years after surgery. Levels of FCR were not different 
for men or women, age, or medical characteristics. These findings are partly in line with 
the recent systematic review of Simard and colleagues [11] which showed moderate 
evidence (4 studies evidence; 12 studies no evidence) for a relation between FCR  and 
gender, and only weak to moderate evidence for a relation with disease and treatment 
characteristics. Although a relation between FCR and age is often observed in the litera-
ture, there was no significant correlation in this study. A possible explanation could be 
that there participated both males and females in this study. The systematic review of 
Simard and colleagues[11] namely revealed that in 18 studies, of which eight included 
samples of only males, no significant relationship with age was found. It might be the 
case that there is no association between age and FCR in male cancer survivors, and 
therewith, the relationship in this mixed sample disappeared. 
In accordance with previous studies, the CRC survivors in this study reported a good 
global quality of life [6]. However, there were large statistically and clinically relevant 
differences between individuals who reported high or low levels of FCR, with high FCR 
being associated with a lower general quality of life, lower emotional functioning, role 
functioning and social functioning, and more problems with body image and future 
perspective. Furthermore, individuals with high FCR had higher levels of general distress 
and post-traumatic stress symptoms, such as avoidance and intrusions. This is consistent 
with the results of studies among cancer patients reporting that intrusive thoughts are 
more frequently related to future-oriented fears, such as FCR [34-38]. Simard and col-
leagues [13] revealed that the nature of these intrusive thoughts associated with FCR 
shares characteristics with worries, negative and uncontrollable thoughts on an issue 
whose outcome is uncertain but which contains the possibility a negative outcome[39]. 
More severe FCR tends to resemble obsession, defined as recurrent thoughts and images, 
experienced as intrusive and inappropriate, causing anxiety and psychological distress 
[40]. This was also supported by the results of this study since CRC survivors with high 
FCR reported  unpleasant thoughts or images such as death, suffering, or consequences 
for family when thinking about the possibility of cancer recurrence as one of the most 
frequently occurring features of FCR. Furthermore, the results showed that high FCR is 
characterized by reactions to specific triggers, negative thoughts and feelings accom-
panied by reassurance behavior. Interestingly, reassurance behavior mainly consisted 
of contact with one’s medical professional. Body checking occurred less frequently. An 
explanation for this finding might be that it is more difficult for CRC survivors to check 
their body for symptoms of recurrence than for breast cancer survivors. CRC survivors 
might be more focused on their defecation than on their body. Since CRC survivors with 
high FCR do not experience their fear as excessive or unreasonable (insight) but the 
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focus seems meanwhile to be on dysfunctional thoughts or behaviors, CRC survivors 
with high FCR may benefit from cognitive behavior therapy [41-44].
The study had some limitations. The low response rate (38%) and small sample size 
means that results might not be representative. It is possible that survivors who have 
been disease-free for a number of years might not want to think about hospitals and 
cancer research. Alternatively, it might be the survivors with the most severe problems, 
with high levels of FCR, or distress who do not participate. Despite the small sample size, 
statistically and clinically relevant differences were found between individuals with high 
and low levels of FCR, and descriptive analysis was possible.
Another limitation is the difference between responders and non-responders, which 
could be indicative of selection bias. However, compared to the Dutch cancer popula-
tion at the time of this study, age categories, and gender distribution were quite similar, 
indicating that is was a representative sample [45].
Although reliability and criterion validity of the CWS were established in a population 
of CRC survivors, not all components of validity were assessed. Future research should 
address multiple components of validity.
ConClusions
This study emphasizes the need to focus on specific problems rather than general QoL, 
but these findings should be confirmed with a larger sample using a prospective design. 
We are currently investigating FCR, distress, and QoL in the first year after the diagnosis 
of CRC. Future research should aim to develop an evidence-based intervention for CRC 
survivors with high FCR, and the results of the current study may provide starting points 
for such an intervention.
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AbstRACt
background In understanding fear of cancer recurrence (FCR), it is important to con-
ceptualize it as a multidimensional problem in which internal or external cues trigger 
interpretations and cognitions of the threat of cancer, leading to an increase of fear. 
This fear may result in dysfunctional behaviors, such as limited planning, body checking 
and seeking professional advice, again enhancing an increased fear response. This study 
simultaneously assessed the relations in the hypothesized model of FCR.
Methods 1205 breast cancer survivors, 0-5 years after the end of primary breast cancer 
treatment were invited to participate in this study. Participants received a questionnaire 
booklet including questionnaires on demographics and psychosocial variables includ-
ing FCR. Data analysis consisted of the estimation of direct and indirect effects in simple 
and multiple mediator models.
Results A total of 460 women (38%) participated in the study. Median age was 55.8 years 
(range 32 – 87). Indirect effects via FCR were found for all mediation models with limited 
planning (R2=.28)  and body checking (R2=.11-.15) as behavioral response variables, with 
the largest effects for limited planning. A direct relation was found between feeling sick 
and seeking professional advice, not mediated by FCR. Different moderators were found 
for each of the models tested. 
Conclusions In the first tested models of FCR, all internal and external cues were as-
sociated with higher FCR. In the models with limited planning and body checking as 
behavioral response, an indirect effect of cues via FCR was found. An evidence-based 
model of FCR may facilitate the development of appropriate interventions to manage 
FCR in breast cancer survivors.
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intRoduCtion
With increasing breast cancer survival rates, it has become more important how survi-
vors deal with psychosocial consequences of the disease and treatment. After curative 
treatment and in the absence of a physical threat, breast cancer survivors frequently 
have worrying thoughts about ‘the possibility that the cancer may return or progress in 
the same organ or in a different part of the body’, which is widely adopted as definition 
for fear of cancer recurrence (FCR) [1]. Among breast cancer survivors FCR is commonly 
identified as an unmet psychosocial need for which they want help [1-6]. When FCR 
becomes severe it coincides with psychological distress, lower quality of life and func-
tional impairments [7-9]. Since guidelines for the treatment of FCR are lacking, health 
care providers often do not know how to deal with FCR. In developing adequate care, 
identifying potential targets for interventions is important. Furthermore, available mod-
els in which possible predictors are part of a multidimensional entity are scarce. Only 
three theoretical models have been presented in literature; two therapeutic models 
developed to guide new interventions [10,11] and the explanatory model of Lee-Jones 
which is most often cited by researchers [12]. All three models incorporate the cognitive 
and emotional reaction to cues. None of these models have been tested.  
Lee-Jones and colleagues (1997) proposed a theoretical model based on Leventhal’s 
Self Regulation Model of Illness [13]. This self-regulation model hypothesizes that ex-
ternal and internal stimuli generate a subjective perception of a somatic problem or 
health threat and concomitant emotions (eg., fear/distress), leading to coping strategies 
and appraisal of health outcomes. Representations, coping strategies, and appraisal are 
affected by self and social context. 
Leventhal’s theoretical framework is not specific to FCR. However, it gives insight in why 
patients react differently to the news that they have cancer and why some are more fear-
ful than others for cancer recurrence. In accordance with Leventhal’s model, Lee-Jones 
and colleagues hypothesized that a person’s FCR will vary depending on their cognitive 
reaction to illness. The formulation of FCR proposed that cues play a role in activating 
cognitive responses associated with FCR. On the one hand internal (somatic) cues are 
interpreted as reminders of the disease or as threat that the illness may have returned. 
On the other hand external cues associated with the disease (eg., medical check-ups, 
exposure to media) will increase worrying thoughts about a possible recurrence. High 
FCR can result in anxious preoccupations followed by personal checking behavior, 
uncertainty, and consequently limited planning for the future, or misinterpretation of 
neutral bodily symptoms and, as a consequence, seeking professional advice. 
Recently, three systematic reviews on FCR revealed a growing body of research 
on predictors and correlates of FCR [7-9]. Overall, the three reviews demonstrated an 
association between FCR and age, presence or severity of physical symptoms, psycho-
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logical distress, quality of life or functioning impairments, coping responses, cues (new 
symptoms, pain and follow-up appointments), personality characteristics and social 
support. We incorporated the main findings from this literature update in the model 
of Lee-Jones, leading to a new model of FCR (See Fig. 1). Every women confronted with 
the diagnosis of breast cancer has to learn to cope with normal cues (eg., flu / television 
programs about cancer). It is hypothesized that women with certain characteristics that 
can make one vulnerable to FCR (eg., less optimism) perceive a higher personal risk of 
developing a recurrence which is accompanied with fear. It is also hypothesized that 
because of their high FCR and elevated perceived risk of recurrence, these women seek 
more reassurance from health professionals, frequently engage in body checking and 
experience limited planning for the future. The aim of the present study was to test the 
new hypothesized model of FCR and test the moderating and mediating relationships in 
the model to discover underlying mechanisms of FCR. 
MEthods
Participants
1205 eligible breast cancer survivors from three hospitals in the Netherlands (Isala 
Klinieken Zwolle, n=461, Jeroen Bosch Hospital ‘s-Hertogenbosch, n=410 and Canisius 
Wilhelmina Hospital Nijmegen, n=334) were contacted by an information letter of 
their physician. It was explicitly stated in this letter that women both with and without 
FCR could participate. The breast cancer survivors were assessed 0–5 years after their 
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Fig. 1. Hypothesized model of FCR.
93
Towards an evidence-based model of FCR
Ch
ap
te
r 6
primary treatment. To be eligible, women had to be treated with curative intent and 
disease-free at the time of participation. Hormonal therapy or treatment with a specific 
antibody (trastuzumab) were not exclusion criteria. All participants had to be able to 
read and write in Dutch. 
Procedure
Documented approval from the local Ethics Committee was obtained prior to start of 
the study. By returning informed consent, the women agreed to participate. As part of 
an ongoing prospective study, participants received a questionnaire booklet including 
questionnaires on demographic, medical and psychosocial variables. Questionnaires 
could either be filled in online or in paper-and-pencil form.
instruments
Cues – Internal cues
Attention to internal bodily sensations 
The Body Vigilance Scale (BVS) measures the tendency to attend to internal bodily 
sensations (internal cues). The BVS consists of five questions. Four questions concern 
the degree of attentional focus, perceived sensitivity to changes in bodily sensations, 
the average amount of time spent attending to sensations, and the frequency of at-
tending to bodily sensations. The fifth question  concerns the severity of 13 anxiety-
related bodily sensations (heart palpitations, chest pain, numbness, tingling, shortness 
of breath, faintness, vision changes, dizziness, hot flash, sweating/clammy hands, upset 
stomach, nausea, choking/throat closing). Items are rated on a 10-point VAS [16]. In this 
study Cronbach’s α = .91.
Feeling sick
Feeling sick as internal cue was assessed with a single item of the subscale Triggers of 
the Fear of Cancer Recurrence Inventory (FCRI): ‘When I feel unwell physically or when I 
am sick, I think about the possibility of cancer recurrence’. This item is rated on a 5-point 
Likert scale ranging from 0-4. The FCRI is a reliable and valid self-report scale [17]. 
Cues – External cues
External cues – contact with health professionals
External cues related to contact with health professionals were measured with two 
items of the subscale Triggers of the FCRI: ‘An appointment with my doctor or other 
health professional’ and ‘Medical examinations make me think about the possibility of 
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cancer recurrence’. Both items are rated on a 5-point Likert scale ranging from 0-4 [17]. 
In this study Cronbach’s α = .84.
External cues – media and social context
External cues related to the media and social context were assessed with four items of 
the subscale Triggers of the FCRI: ‘Television shows or newspaper articles about cancer 
or illness’, ‘Conversations about cancer or illness in general’, ‘Seeing or hearing about 
someone who is ill’ and ‘Going to a funeral or reading the obituary section of the paper 
make me think about the possibility of cancer recurrence’. Items are rated on a 5-point 
Likert scale ranging from 0-4 [17]. In this study Cronbach’s α = .89.
Fear of cancer recurrence – Cognitions and emotions
Fear of Cancer Recurrence: severity
The Cancer Worry Scale (CWS) has been used in research to assesses concerns about 
developing cancer (again) and the impact of these concerns on daily functioning. The 
eight items of the CWS are rated on a 4-point Likert scale ranging from ‘Never’ to ‘Almost 
always’. Scores range from 8 to 32 [18]. The CWS was validated for breast cancer survi-
vors. A diagnostic cut-off score of 14 or higher (sensitivity 77%; specificity 81%) indicates 
severe feelings of fear of cancer recurrence [19]. In this study Cronbach’s α = .88.
Consequences
Limited planning for the future
Limited planning for the future was assessed with one item of the subscale Functional 
Impairments of the FCRI: ‘my ability to make future plans or set life goals are disrupted 
by my thoughts or fears about the possibility of cancer recurrence’. Items are rated on a 
5-point Likert scale ranging from 0-4 [17]. 
Seeking professional advice
Seeking professional advice was assessed with two items of the subscale Reassurance 
of the FCRI. When I think about the possibility of cancer recurrence, I use the following 
strategies to reassure myself: ‘I call my doctor or other health professional’, ‘I go to the 
hospital or clinic for a an examination’. The items are rated on a 5-point Likert scale rang-
ing from 0-4 [17]. In this study Cronbach’s α = .85.
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Body checking
Body checking was assessed with a single item of the subscale Reassurance: ‘I examine 
myself to see if I have any physical signs of cancer’. This item is rated on a 5-point Likert 
scale ranging from 0-4 [17]. 
Moderator – Personal characteristics
Personality
Personality factors were measured by the Big Five Inventory (BFI) including Extraversion, 
Neuroticism, Conscientiousness, Agreeableness, and Openness to Experience. The BFI 
consists of 44 items, each scored on a 5-point Likert scale [20]. In this study Cronbach’s 
α = .63.
Optimism
The Life Orientation Test (LOT) was developed to assess individual differences in general-
ized optimism versus pessimism. The LOT consists of 12 items, each scored on a 5-point 
Likert scale [21]. In this study Cronbach’s α = .54.
Self-esteem
The Rosenberg Self-Esteem scale was used to measure self-esteem with 10 items scored 
on a 5-point Likert scale. Higher scores indicate higher self-esteem [22]. In this study 
Cronbach’s α = .20.
Moderator – Social context
Social Support 
Social support was measured by the Social Support List subscale Discrepancies (SSL-
D) [23]. The SSL-D measures the perceived discrepancy in actual support and desired 
support. The questionnaire assesses six types of social support: emotional interactions, 
problem-focused emotional support, esteem support, instrumental interactions, social 
companionship, and informational support. Total scores of the SSL-D range from 34-
102. The SSL-D has good reliability and content validity [24] and was used in studies of 
patients with somatic complaints [25]. In this study Cronbach’s α = .94.
data-analyses
All analyses were performed with SPSS version 20.0. Relationships between FCR and 
demographic and medical variables were assessed with independent sample t-tests and 
one-way ANOVAs. Pearson product moment correlations between FCR severity (CWS) 
and other variables of r .20 - .80 were incorporated in the model. We estimated the 
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model parameters with PROCESS [26]. PROCESS is a plug-in for SPSS which enables easy 
estimation of direct effects, indirect effects, and interactions. In addition, PROCESS esti-
mates the significance of the indirect effect using bootstrapping which is the preferred 
method [27]. Direct and indirect models were analyzed separately for each exogenous 
variable. Therewith 12 mediation models were analyzed. We could have simplified this by 
performing three mediation analyses, however, we also performed moderation analyses 
on the same mediation models. Since PROCESS does not allow moderated mediation 
analyses with more than one exogenous variable, we have analyzed all exogenous 
variables separately in the mediation analyses as well as in the moderated mediation 
analyses. 
REsults
demographic and medical characteristics
Of the 1205 women who were eligible and asked to participate in this study, 565 (47%) 
were interested in receiving more information about the study. Of these, 460 women 
signed informed consent and returned the questionnaire booklet. Study participants 
were compared to 539 non-responders demonstrating that participants were signifi-
cantly (t(993,635) = 5.77, p <.001) younger (M = 56.69, SD = 9.6) than non-responders 
(M = 60.64; SD = 11.9). Of the women who filled out the CWS, 250 (55%) had high FCR 
according to the cut-off point >13 on the CWS. Table 1 shows the patient- and treatment-
related characteristics of the sample. 
Relation FCR and demographic/medical variables
With regard to demographic variables, a significant relationship was found between FCR 
and education (F(2,441) = 5.26, p = .006), indicating that women who completed tertiary 
education (M = 13.78, SD = 3.6) experienced less FCR than women who completed pri-
mary (M = 15.44, SD = 4.9) or secondary education (M = 15.00, SD = 4.2). Furthermore, 
there was a significant relationship between FCR and having children (t(445) = -2.37, p = 
.018), indicating that women with children (M = 14.94, SD = 4.3) experienced more FCR 
than women without children (M = 13.66, SD = 4.0).  No relationship was found between 
FCR and age (r = -.04, p = .415), or between FCR and partnership (t(438) = -.13, p = .899). 
No significant relationships were found between FCR and medical variables; time since 
diagnosis (r = -.04, p = .381), chemotherapy (t(448) = -.11, p = .909), radiotherapy (t(447) 
=  .55, p = .584), or hormonal therapy (t(448) = -.12, p = .906).
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Relation FCR and psychosocial variables
The personality factors ‘conscientiousness’, ‘agreeableness’ and ‘openness to experience’ 
were not included in the analyses because their correlation with FCR was <.20. All other 
psychosocial variables displayed correlations between .20 and .70.
Mediation Analysis
Fig. 2 shows the twelve conceptual models for the associations between four types of 
cues (external (1 and 2), internal (3 and 4)), FCR and three separate behavioral responses 
(A limited planning for the future; B seeking professional advice; C body checking). 
Results of the mediation analyses are displayed in Table 2. In all models, there was a 
positive significant relation between cues and FCR (pathway a). The relation between 
FCR and behavioral responses (pathway b) was significant in almost all models except 
for the model B1 ‘media and social context → FCR → seeking professional advice’ and 
the model B3 ‘feeling sick → FCR → seeking professional advice’. In these two models 
there was no direct relationship between FCR and seeking professional advice. In model 
table 1. sample characteristics (n = 460)
Age (years) Mean = 56.7, SD=9.6; range 32-87
Marital status: married/partnership 367 (80%)
Children: yes 382 (83%)
Educational level
Primary 89 (19%)
Secondary 224 (49%)
Tertiary 139 (30%)
Unknown 8 (2%)
Employment status
Employed 217 (47%)
Home management 145 (32%)
Retired 91 (20%)
Volunteering 66 (14%)
Sick leave 37 (8%)
Disablement insurance act 33 (7%)
Unemployed / others 90 (20%)
Time since initial diagnosis (years) Mean = 2.8; SD = 1.3
Surgery: yes 460 (100%)
Additional treatment
Chemotherapy 330 (72%)
Radiotherapy 348 (76%)
Hormonal therapy 296 (64%)
Trastuzumab 61 (13%)
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Fig. 2. Twelve models that represent the hypotheses about the triggers and consequences of FCR
table 2. Direct and indirect effects of the individual models
Dep. Var. Model Trigger R2 a b c Indirect 
effect
LLCI-ULCI1
li
m
it
ed
 p
la
nn
in
g
A1 Media and social context .278 2.64* .128* .000 .3397* .2576 - 
.4326
A2 Contact with health 
professionals
.280 1.99* .131* -.013 .2598* .2009 - 
.3211
A3 Feeling sick .277 2.02* .122* .034 .2468* .1784 - 
.3199
A4 Bodily sensations .282 0.19* .132* -.005 .0248* .0171 - 
.0335
se
ek
in
g 
pr
of
es
si
on
al
 
ad
vi
ce
B1 Media and social context .026 2.64* .021 .068 .0550 -.0262 - 
.1323
B2 Contact with health 
professionals
.023 1.99* .031* -.001 .0625* .0108 - 
.1207
B3 Feeling sick .043 2.02* .012 .124* .0243 -.0284 - 
.0938
B4 Bodily sensations .031 0.19* .025* .010 .0047* .0006 - 
.0096
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B3 however, there was a significant effect of pathway c indicating that feeling sick was 
directly associated with seeking professional advice. Furthermore, significant effects of 
pathway c were found in the models C3 and C4 with direct effects for feeling sick → 
body checking and bodily sensations → body checking. Indirect effects were found for 
all models with limited planning and body checking as behavioral response variable, 
with the largest effects for limited planning. For the models with ‘seeking professional 
advice’ as outcome, the indirect effect was only significant but small for the model B2 
‘contact with health professionals → FCR → seeking professional advice’ and model B4 
‘bodily sensations → FCR → seeking professional advice’.  
Moderated Mediation Analysis
Table 3 shows the results of the moderated mediation analysis. Social support was not 
found to be a significant moderator in any of the models tested. The models in which 
bodily sensations were defined as cues (A4, B4, C4) were not moderated by any of the 
moderators. Furthermore, the models that did not show an indirect effect or had really 
small indirect effects in the mediation analyses (B1, B3 and B4) showed no moderated 
mediation effect. All other models (A1, A2, A3, B2, C1, C2, C3) revealed several moderators 
per model. Self-esteem was the only moderator that moderated the mediation effect of 
all these models indicating that more self-esteem was associated with less FCR affecting 
the behavioral response. Neuroticism also moderated the mediation effect except for 
the models where ‘feeling sick’ was the cue (A3, C3). Optimism only moderated the me-
diation effect in models where the outcome variable was ‘seeking professional advice’ 
(B2) or ‘body checking’ (C1, C2) except for model C3 where ‘feeling sick’ was the cue. 
Last, extraversion moderated the mediation effect in model A1, C1 and C3 indicating 
that more extraversion was associated with less FCR affecting the behavioral response 
‘limited planning’ and ‘body checking’. 
table 2. Direct and indirect effects of the individual models (continued)
Dep. Var. Model Trigger R2 a b c Indirect 
effect
LLCI-ULCI1
bo
dy
 c
he
ck
in
g
C1 Media and social context .111 2.64* .084* .039 .2214* .1287 - 
.3096
C2 Contact with health 
professionals
.117 1.99* .076* .099 .1522* .0918 - 
.2186
C3 Feeling sick .124 2.02* .073* .118* .1466* .0876 - 
.2190
C4 Bodily sensations .151 0.19* .071* .031* .0133* .0071 - 
.0197
1 Lower and upper limits of the bootstrap confidence interval of the indirect effect.
*p <.05
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disCussion
To the best of our knowledge this is the first study to test the hypothesized model of 
Lee-Jones [12].  The results showed evidence for almost all relationships in the model 
except for the indirect effect with seeking professional advice as behavioral response. 
The models with limited planning for the future as behavioral consequence showed the 
largest effects. In the model with seeking professional advice as behavioral response, 
only very small indirect effects were found for two types of cues (external triggers 
related to oneself; internal bodily sensations). Furthermore, there was a direct relation 
between feeling sick and seeking professional advice and a marginal significant direct 
relation between bodily sensations and seeking professional advice. These effects point 
in the direction that when patients experience symptoms they directly contact their 
health professional for advice and not as an indirect consequence of worrying thoughts 
or anxious feelings.     
Although previous studies pointed out some moderating variables (social support 
[28-31]; optimism[31-35]; self-esteem[36-39]; personality factors[37]), the results of the 
present study showed a very inconsistent pattern. Self-esteem was the only factor that 
consistently moderated the indirect relationships indicating that higher self-esteem 
was associated with less FCR and therewith a smaller effect on the behavioral response. 
table 3. Moderated mediation
Dep. Var. Model Trigger Optimism Self esteem Neuroticism Extraversion Social 
Support
li
m
it
ed
 p
la
nn
in
g A1 Media and social context - -.0073* .0699* -.0511* -
A2 Contact with health 
professionals
- -.0086 .0538* - -
A3 Feeling sick - -.0056* -
A4 Bodily sensations - - - - -
se
ek
in
g 
pr
of
es
si
on
al
 
ad
vi
ce
B1 Media and social context - - - - -
B2 Contact with health 
professionals
-.0017* -.0021* .0123* - -
B3 Feeling sick - - - - -
B4 Bodily sensations - - - - -
bo
dy
 c
he
ck
in
g C1 Media and social context -.0048* -.0047* -.0461* -.0341* -
C2 Contact with health 
professionals
-.0041* -.0050* .0328* - -
C3 Feeling sick - -.0033* - -.0323* -
C4 Bodily sensations - - - - -
*p <.05
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However, these results should be interpreted with caution since the Cronbach’s alpha 
of the Rosenberg Self-esteem scale was very low (α =.20) referring to a methodological 
problem that was not expected based on previous studies in oncology samples using 
this scale [39,40].
Where it was assumed that more optimistic women would experience less fear and 
therefore would have a more optimistic vision of the future, the results did not confirm 
this hypothesis. In contrast to what we expected, optimism did not moderate the media-
tion effect in the models with limited planning for the future as behavioral response. 
Again interpretation of the data is difficult since the Cronbach’s alpha of the scale was 
suboptimal (α =.54). Neuroticism moderated the same mediation models as self-esteem 
except the models where ‘feeling sick’ was the cue. For these models no moderated 
mediation effect was found. This could indicate that being neurotic does not have a 
strengthening effect on the relationship between internal cues and higher levels of fear, 
as it does in the case of external cues. Extraversion was found to be an inconsistent mod-
erator, with some models supporting it and others not. In previous systematic reviews 
social support was found as protector in that high levels of social support were related 
to lower levels of FCR [7,9]. In the present study social support was not found to be a 
significant moderator, which might indicate that FCR is a more intrapersonal than inter-
personal phenomenon. None of the models tested which included bodily symptoms 
as cues were moderated. Also in the mediation models with bodily symptoms as cues, 
the indirect effects were small. This could probably be explained by the fact that the 
other types of cues and behavioral responses were derived from the FCRI which focused 
specifically on FCR whereas the bodily symptoms items were not filled out with respect 
to feelings or thoughts about FCR.  
With regard to the relationship between FCR and demographic or medical variables, 
only lower education and having children were associated with higher FCR. Although 
age is commonly reported in literature reviews [7-9] to be associated with FCR, we 
did not find a relationship in this study. The association between FCR and age might 
already have been present before the start of the study since study participants were 
significantly younger than non-respondents. Since participants were aware of the fact 
that the purpose of the study was FCR, it is plausible that there was already a selection 
in signups for the study as confirmed by the moderate response rate of 38% and the 
relatively high percentage of 55% highly fearful survivors. Selection bias is an aspect 
that should be taken into account when designing research on FCR since a proportion of 
survivors recognize their FCR and express a need for help whereas other survivors cope 
with FCR by avoiding threat, including study questionnaires.  
A limitation of this study is the cross-sectional design, which makes it difficult to draw 
conclusions about causality. Although the basis of this research was a strong theoretical 
model proposed in the literature, future research should focus on the direction of the 
Chapter 6
102
relationships within the model to further strengthen our theoretical knowledge of FCR. 
The results of this study might have future implications and suggestions for different 
professions. For clinicians it is important to keep in mind that patients are very aware 
of bodily symptoms and that FCR is also triggered by information about cancer in their 
surroundings. Clinicians may provide tailored and correct information about one’s 
disease status and education about symptoms that require immediate action versus 
symptoms that might be innocent. Once they received this information, patients might 
be better able to reassure themselves and adopt a wait and see approach. For psycholo-
gists the model confirms that a cognitive behavioral therapeutic approach might be a 
good intervention for high FCR. More specifically, the results of this study indicate that 
interventions targeting FCR may benefit from incorporating modules on making new 
plans for the future and the regulation of bodily checking behaviors. For researchers this 
study gives insight into how FCR model testing can be performed. Replication of this 
study in a longitudinal design is needed, taking into account some methodological con-
siderations about the best questionnaires to use for risk-factors and protective factors. A 
greater understanding of these factors associated with FCR may assist the development 
of evidence-based screening programs and treatments for FCR.
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intRoduCtion
With the rising numbers of cancer patients living with or beyond cancer for prolonged 
periods of time, increasing attention has been paid to the relatively new and evolving 
field of fear of cancer recurrence (FCR). Although in the last fifteen years many studies 
were conducted, approaches to conceptualize, measure and treat FCR were fragmented. 
Many questions still remain: eg., ‘Why do some patients suffer more from FCR than oth-
ers?’, ‘How can we detect those patients who are in need for help?’ ‘Is this a problem 
for which we need specific interventions?’ In 2015 an international research consensus 
meeting with international experts in the field of FCR and two patients was held in Ot-
tawa, Canada, in order to 1) reach consensus internationally about the definition of this 
phenomenon and 2) set a basis to start research that builds from this new definition 
into assessment tools, clinical definitions and interventions. The studies and results 
presented in this thesis were part of the discussion in this meeting. As a result of the 
discussion, a special interest group (SIG) FORwardS was formed. This SIG is hosted by 
the International Psycho-Oncology Society (IPOS) [1]. In this chapter the studies and 
results of this thesis will be evaluated on their merits and shortcomings. Furthermore, 
directions for future research will be formulated. 
dEFinition: FEAR oF RECuRREnCE oR FEAR oF PRoGREssion?
Different definitions are used to describe fear of cancer recurrence in the literature. 
Already in 1981, Northouse [2] described FCR as ‘the degree of concern reported by 
subjects about the chances of cancer returning at a future time’. In order to construct a 
new questionnaire, Vickberg [3] formulated FCR as ‘the fear that the cancer will return 
or progress in the same organ or in another part of the body’. This definition has been 
widely adopted by researchers and clinicians and recently adapted by Simard and Sa-
vard [4] who added the concept of worry: ‘the fear or worry that the cancer will return 
or progress in the same organ or in another part of the body’. Although the previous 
definitions were specific to cancer, a definition that can be applied to chronic diseases 
in general was proposed by Herschbach and colleagues [5]: ‘the fear that the illness will 
progress with all its biopsychosocial consequences or that it will recur,’ also referred to 
as fear of progression (FoP). 
In this thesis, the studies on the Cancer Worry Scale (chapter 2), selective atten-
tion (chapter 3), the model of FCR (chapter 6) and FCR in colorectal cancer survivors 
(chapter 5) focused on curatively treated cancer patients. Because of the curative intent 
of treatment in these samples, the term recurrence was used in the definition of FCR. 
The study on GIST patients in chapter 4  highlights the importance of incorporating 
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the concept of progression in a complete definition. Since more treatment options and 
lines of medicine are becoming available to cancer patients with metastatic disease, 
an increasing number of patients are receiving ongoing treatment for long periods [6-
8]. Therewith it is semantically and basically different for patients and professionals to 
use the term recurrence or progression. Although a higher percentage of high fearful 
patients was found in the GIST population (chapter 4) compared to the studies with 
breast cancer survivors and colorectal cancer survivors, there were no differences in 
manifestations of the fear (triggers, consequences, emotions) between patients who 
were alive with the disease (FoP) and those who had no evidence of disease (FCR). On 
the one hand this could be interpreted as evidence that the descriptions of ‘fear of recur-
rence’ and ‘fear of progression’ are the same on a conceptual level [9]. On the other hand 
it might point to the direction that more research is needed to investigate differences in 
manifestations of the fear between patients who are on palliative treatment trajectories 
and patients who show no evidence of disease. Since the focus of many studies and 
questionnaires is on curatively treated patients, little is known about the experiences 
of patients on active ongoing treatment in the palliative setting. Taking this discussion 
of recurrence versus progression into account, in the expert meeting consensus was 
reached on a new definition of FCR: ‘fear, worry or concern about cancer returning or 
progressing’ [1]. This definition retains a cancer-specific definition because of the already 
established recognition of this concept worldwide, and makes only small revisions to 
previous proposed definitions. It seems that this definition suits both curatively treated 
patients and patients on palliative treatment, because it covers the uncertainty of a new 
manifestation of cancer or increased disease activity, and is therefore comparable on a 
conceptual level. Despite revisions to the definition, the literature still contains the terms 
‘fear of progression’ and ‘fear of recurrence’.  A recommendation for future research and 
practice should be to adapt descriptions of FCR in questionnaires to the new definition 
and design new research on FCR in patients on palliative treatment to investigate if the 
description of FCR and already established cut-off scores can be retained. 
AssEssMEnt: ConsCious oR unConsCious? 
Gold-standard measure
In order to help cancer survivors who suffer from high FCR, the identification of these 
cancer survivors has become a matter of priority. Therefore, researchers and clinicians 
are in need of a standardized assessment instrument that adequately evaluates FCR 
and distinguishes between normal and high levels. The optimal strategy to determine 
whether a screening tool is valid to identify a specific condition is to compare its result 
with a ‘gold standard’ measure that refers to the best performing measure available 
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[10]. In psychology, structured clinical interviews are regularly used as gold standard 
measures (eg., the Structured Clinical Interview for the Diagnostic and Statistical Manual 
of Mental Disorders (SCID) to identify anxiety disorders [11]). For such a gold standard, 
consensus about the definition and what constitutes high levels is required. This might 
be a reason for the lack of a gold standard in the field of FCR. Until now, only one semi-
structured interview on FCR (SIFCR) exists. The SIFCR  has been recently developed by 
two psychologist experts in the field of psycho-oncology [10], based on the content and 
format of the SCID and literature on FCR. On the basis of this semi-structured interview 
cut-off scores are established for the severity subscale of the fear of cancer recurrence 
inventory (FCRI-SF), frequently used by researchers to define high FCR. 
Cut-off scores
Besides the use of a gold-standard measure, establishing cut-offs scores also relies on 
the interpretation of psychometric properties (sensitivity versus specificity) of the instru-
ment. In the context of FCR assessment, sensitivity refers to the proportion of individuals 
who experience high FCR  having a positive test result, whereas specificity refers to the 
proportion of negative test results corresponding to low fearful individuals. For a scale 
to be useful as a screening instrument, the proposed cut-off score should maximize the 
sensitivity because the purpose of screening is to identify as many fearful patients as pos-
sible. To be used as a diagnostic instrument, it should maximize the specificity because 
a diagnostic instrument should avoid misdiagnosis of high FCR as much as possible. To 
be useful as an instrument to differentiate high FCR from low FCR, it should have high 
sensitivity and specificity, which maximizes the proportion of patients whose test results 
are accurate [12]. Since the studies described in this thesis were observational and not 
primarily focused on screening (high sensitivity) or for instance inclusion in an interven-
tion study (high specificity), we choose for a cut-off score on the Cancer Worry Scale that 
maximized the proportion of patients with accurate test results (both sensitivity and 
specificity around .80; chapter 2). Based on these statistical considerations regarding 
sensitivity and specificity, it was difficult to compare the performance of the CWS to 
detect high FCR with the later published and frequently used FCRI-SF. The FCRI-SF pro-
posed two cut-off points, one for screening and one for optimal specificity which require 
different considerations about the psychometric properties. Although the cut-off scores 
were based on different psychometric considerations, the study on colorectal cancer 
survivors (chapter 5) shows that there was agreement between the CWS and FCRI-SF 
concerning the presence or absence of a high FCR in 87% of the cases indicating that 
these two instruments performed in a comparable way. However, recently a replication 
of the study by Simard and Savard [10] in which the cut-off scores were defined based on 
the semi-structured interview as gold standard was conducted by Jones and colleagues 
[13], showing that a cut-off score of 22 on the FCRI-SF was associated with optimal 
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sensitivity and specificity rates for the screening of high levels of FCR. This cut-off score 
is remarkably higher than the cut-off score of 13 that was previously recommended 
[10]. However, this higher cut-off score is in line with the observations of clinicians who 
see patients with high FCR or select them for an intervention study. They often report 
that by using higher cut-off scores those patients are selected that display fear that is 
dysfunctional and interfering with daily life. Obviously more research is needed to de-
tect the optimal cut-off score but we can tentatively state that both the FCRI-SF (cut-off 
score 13) and CWS (cut-off score 14) are able to detect those patients with moderate to 
high levels of FCR, but these are probably not suitable for detecting those patients who 
have excessive FCR and are in need for help. This is an important fact to keep in mind 
when reading and interpreting the chapters in this thesis. We believe that the ‘moderate 
to severe’ FCR samples included in these studies are appropriate for the observational 
and descriptive aims of this thesis. However, these samples would not be well suited to 
include in an intervention study specifically tailored to FCR since the need for help in 
these patients may be less urgent. Recommendations for future research based on this 
thesis would be to either validate the Cancer Worry Scale based on a structured clinical 
interview or validate the FCRI-SF for the Dutch population and use the higher cut-off 
score. Meanwhile in the refinement and translation of a gold standard, a solution among 
researchers might be to use the 10% highest scores to make comparisons between dif-
ferent measurement tools possible.    
self-report versus implicit measures
Where traditionally anxiety was measured with self-report questionnaires (eg., Hos-
pital Anxiety and Depression Scale, Visual Analogue Scale) there is an emerging field 
of anxiety assessment which relies on the use of implicit processes. Implicit processes 
refer to processes that are not readily captured by conscious introspection, are difficult 
to control, are efficient or effortless, can occur unintentionally or outside of conscious 
awareness [14], but that nevertheless influence behavior [15]. Assessment of implicit 
processes has already been performed with different tasks (eg., dot-probe task [16]; 
emotional Stroop task [17]) in different types of anxiety (eg., generalized anxiety disor-
der [18], social anxiety [19], spider phobia [20]). With a realistic threat such as FCR several 
methodological difficulties appear in both self-report and implicit assessment. First, it is 
important to keep in mind the timing and setting of assessment.  It is known from the 
results of chapter 6 of this thesis that FCR is associated with medical check-ups and 
doctor appointments. Patients are nervous and anxious in the week(s) before a medi-
cal examination or check-up and relieved after hearing good news about their medical 
condition. Furthermore, patients can become anxious following a variety of triggers (eg., 
hearing of someone who has received a cancer diagnosis, Pink Ribbon month October 
for breast cancer). For research purposes it is important, however often difficult, to take 
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into account these ‘confounding’ factors. With regard to the setting, from a classical con-
ditioning viewpoint visiting the hospital can be accompanied by memories, associations 
and feelings of the period of being diagnosed and treated for cancer and this might 
elevate levels of fear. As the latter could have been a confounding factor in the study on 
implicit processes (chapter 3), we believe that assessment of FCR should preferably not 
take place in a hospital setting. Second, a specific question on the need for help can be 
used to indicate the severity of FCR. Often self-report questionnaires do not incorporate 
such a question and with implicit measures it is even more difficult to map the need 
for help. Questions on the need for help can be helpful in defining high FCR. Patients 
scoring high on FCR questionnaires and also reporting a need for help might benefit 
from a more intensive intervention such as face-to-face contact with a psychologist. 
Patients showing a discrepancy between scores on a questionnaire and self-reported 
need for help (high FCR score on questionnaire but no need for help and low FCR score 
but high need for help) might benefit from other types of help/support. For patients 
with low scores on a FCR questionnaire but a high need for help, psycho-education or a 
low intensity intervention such as a self-management program might be helpful. For pa-
tients with high scores on a FCR questionnaire but no need for help, explaining options 
for help by health professionals in case they do need it sometime might be sufficient. 
For the purpose of intervention studies, an indication of need for help and openness 
to the intervention is very important. For research purposes it is not yet clear how to 
handle and interpret these discrepancies. It would be interesting for future studies to 
incorporate a need for help question into FCR measures to compare those patients who 
display a need for help and those who can cope with high FCR themselves. This might 
also be helpful for the development of tailored interventions for FCR. 
Third, research on anxiety disorders demonstrates attentional biases towards threat-
ening information [18-20]. However, until now only two studies on attentional bias have 
been conducted in the field of FCR. In the study of selective attention described in chap-
ter 3 and in a  study of Butow et al. [21], attentional biases were found for cancer-related 
words. The attentional bias in both studies was not different for patients with high or 
low FCR as assessed by self-report, indicating that after the overwhelming experience 
of a cancer diagnosis and treatment, cancer patients in general seem to have a bias 
towards cancer-related words. Although it would be interesting to speculate about this 
discrepancy between self-report and implicit assessment of FCR it might be too early 
to draw the firm conclusion that there exists a discrepancy. The knowledge about and 
materials for measuring FCR in an implicit way is still very premature. There is yet no set 
of validated stimuli that tap into the issue of FCR specifically and there is still debate 
[22,23] about which implicit instrument is best to use in which setting. At this moment 
a prerequisite for research with implicit measures is the exploration and validation of 
useful stimuli. Qualitative studies with patients expressing the content of FCR depicted 
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in words and images might be a useful method for this aim. Furthermore, the use of 
eye-tracking techniques will provide more insight into the direction of attention for cer-
tain stimuli. With use of eye-tracking techniques, a direct and continuous record of the 
allocation of attention over an extended interval of time can be provided for multiple 
stimuli competing for attention [24]. Using eye-tracking technology, attention towards 
or away from certain stimuli can be examined. Taking these considerations into account, 
influencing or modifying these implicit processes might add value to the development 
of interventions for FCR. Positive findings are published of interventions, based on cog-
nitive bias modification (CBM), in which implicit cognitive processes related to anxiety 
are influenced by direct modification of attention via repeated practice on cognitive 
tasks [25-27]. 
Fourth, selection bias is an aspect that is often present in studies of anxious individu-
als and also affects the study of  FCR. It seems that there are two groups of avoiders. 
Firstly there are the patients who acknowledge that they are fearful but show an avoid-
ant reaction as measured by for instance the Impact of Event Scale (IES) [chapter 3 and 
5]. Secondly, there is a group of patients who avoid everything related to cancer (eg., 
hospitals etc.). These patients may not attend follow-up consultations, and are likely 
not to participate in studies on anxiety. To incorporate these individuals in research on 
FCR other options of data collection might be considered. For instance, with the use 
of Internet peer support via contact with other patients in online communities has 
increased. This could be a platform where patients share their feelings or worries with 
other patients. It would be interesting to find out if users of online communities differ 
from  those who participate in research studies and to conduct content analyses of texts 
investigating their topics of concern. 
CouRsE oF FCR
Exploring the course of FCR is necessary for several reasons. First, it gives insight into the 
development and stability of FCR. This is important to provide the appropriate level of 
support to patients. If patients experience high FCR that remains stable or even increases 
over time, longer and more intensive interventions might be needed [28]. Second, pro-
spective longitudinal designs enable us to examine the role of potential determinants 
and consequences of FCR by investigating the direction of relationships. Several longi-
tudinal studies were conducted over the past years [29] with varying follow-up periods 
(3 months [30] to 6 years [31]) and various data collection points (between two [32-38] 
and seven [39]). These variations limit comparison among studies and raise questions on 
how to assess this ‘natural’ course best. At what point in the cancer continuum should 
FCR assessment start? How often should we measure FCR and with what time interval to 
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get a reliable assessment? How to observe and analyze individual fluctuations, and map 
triggers linked to these fluctuations? Is it possible that researchers induce fear by assess-
ing FCR too frequently? Involving patients (or patient advocates) in getting answers to 
these questions would be very helpful. 
With regard to the timing of starting FCR assessment, recruitment of patients and 
collection of data is often difficult in the period before start of treatment. Patients are 
often overwhelmed with the cancer diagnosis or have insufficient time to complete 
the baseline assessment prior to treatment. The few longitudinal studies measuring 
baseline FCR prior to treatment did find highest FCR levels at this point with a significant 
reduction in fear between the pre- and post-treatment assessments [38-41] The reduc-
tion can be explained by the heightened general psychological distress that occurs at 
the time of diagnosis, and distress is usually highly correlated with FCR [42]. Therefore, 
it is questionable if FCR as unique concept can be measured at diagnosis or start of 
treatment. Besides, since the cancer has not been treated yet at this point the concept 
of recurrence is not yet applicable and fear refers to the cancer, its treatment and 
prognosis. It seems that measuring FCR post-treatment is more reliable and easier to 
interpret. With regard to frequency of measuring FCR, most studies report results on 
FCR scores of the total sample. When using for instance two measurement points, an 
increase, decrease or stable level over time is visible. However this does not imply that 
all patients exhibit the same trajectories between the measurement points. Given the 
fact that FCR is linked to multiple triggers (chapter 6) FCR levels might fluctuate over 
time dependent on encounters with certain triggering situations. Dunn and colleagues 
[39] displayed this variability in FCR scores of seven data collection points in a spaghetti 
plot of individual trajectories. To more accurately identify FCR trajectories, it is recom-
mended to include more than two measurement points in studies. Furthermore, in order 
to investigate predictors of these inter-individual differences in initial levels of FCR and 
changes over time, different statistical approaches (eg., multilevel models) should more 
often be adopted instead of the typically used linear or logistic regression analyses 
[39]. With regard to the time interval between consecutive FCR assessments, it remains 
unknown whether FCR can be induced by reminding patients too often of their worries, 
cancer diagnosis or health status. Questionnaires on FCR might then be functioning as 
triggers and compromise the reliability of FCR assessment. It would be interesting for 
future research to investigate this possible phenomenon and determine the optimal 
time interval between assessment points. By asking patients what possibly could have 
influenced their level of FCR at the time of reporting, insight can be gained about pos-
sible triggers. Overall, involvement of experienced clinicians and patients in designing 
novel research could be extremely helpful in solving these issues.
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ModEl And intERvEntions
In chapter 6 the hypothesized theoretical model of FCR proposed by Lee-Jones [43] 
was tested and largely confirmed. Although this model was tested on a cross-sectional 
dataset, it gives insight into the interplay of different variables associated with FCR. 
Replication of the model on longitudinal data is necessary to establish causal relation-
ships. Because the hypothesized theoretical model is agreed upon by international FCR 
experts of the consensus meeting we believe that the confirmed model can be guiding 
for clinicians, psychologists and other health professionals. Chapter 6 revealed relation-
ships between FCR and different types of triggers such as medical check-ups, bodily 
sensations, or media on cancer. Clinicians could play an important role in anticipating on 
these triggers. By giving patients accurate information on their disease status, patients 
will become for instance less fearful of information about cancer (via media or social 
context)  that is not applicable to their individual situation. In addition, patients need 
education and information about bodily symptoms that require serious attention versus 
symptoms that might be relatively innocent belonging to a viral infection for instance. 
If patients know that some symptoms require a wait and see approach for a couple of 
days, this information might be helpful to regulate fear responses. For psychologists, the 
model of FCR can be helpful in designing interventions to normalize FCR. The question 
arises whether interventions should be specifically focused on FCR as a primary outcome, 
or that interventions focusing on emotional adjustment with FCR as a secondary out-
come would be equally effective in reducing FCR. It is difficult to draw firm conclusions 
on this issue since several randomized controlled trials targeting FCR are still in progress 
[44-47]. Little evidence from completed trials is available and insufficient evidence is cur-
rently available to  recommend either specific FCR or generic interventions. Short-term 
effects were found for both FCR specific interventions (two short-group interventions 
(cognitive behavior therapy (CBT); supportive-experiential group therapy) compared to 
care as usual [48]) and generic interventions (6 sessions mindfulness-based stress re-
duction (MBSR) [49]; emotion regulation group [50]; Web-based self-management [51]) 
compared to care as usual, and one generic intervention without a control condition 
(8 sessions MBSR [52]). Of these studies showing a short-term effect, 3 out of 5 studies 
also investigated the long-term follow-up effect [48,50,51]. Only the specific FCR group 
interventions [48] showed a long-term follow-up effect of longer than 6 months. Most of 
the intervention studies used a group session design; however it would be interesting 
for future research to see if there is a difference in outcomes between group session 
interventions [46,48-50,52] and individual therapy [44,45,47,51]. 
Although more research on interventions is needed, the treatment effects of both 
specific and generic interventions are promising and might be a good starting point for 
an ‘umbrella’ approach encompassing multiple interventions tailored to the specific level 
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of fear and need for help for each cancer survivor. Patient education via brochures or 
websites with correct and complete information on FCR might be suitable for survivors 
with low, normal, levels of FCR. For survivors with moderate levels of FCR a low-intensity 
intervention like an online self-management program including modules on FCR could 
be appropriate equipping them with personal skills that support them in dealing with 
FCR. Survivors with high FCR might benefit most from a more intensive intervention 
such as face-to-face CBT or MBSR interventions. 
MEthodoloGiCAl ConsidERAtions oF thE dissERtAtion And FutuRE 
diRECtions
Based on progressive insights gained from the studies described in this thesis, several 
recommendations for future directions can be formulated. As previously mentioned re-
searchers and clinicians need a gold standard measure to detect patients with excessive 
FCR. The questionnaires and associated cut-offs used in our studies to assess severity of 
FCR (Cancer Worry Scale, chapter 2-6; Fear of Cancer Recurrence Inventory, chapter 4,5) 
might not be the optimal instruments to detect excessive FCR. This is due to the current 
lack of a gold standard clinical interview, which in turn is difficult to develop without a 
clear definition of what constitutes clinical levels of FCR. Consensus from psychologists, 
medical doctors and patients should be reached about the manifestations of excessive 
FCR in order to develop and validate a clinical interview. A next step would be research 
focusing on the validation of FCR questionnaires and establishing new cut-off scores ac-
cording to the gold standard clinical interview. Although in chapter 5 a first attempt was 
made to investigate content of FCR, this dissertation did not use a qualitative method. 
This is a limitation since this type of research might be very helpful in gaining insight 
into the manifestations and content of FCR. Furthermore, the evolving area of implicit 
processes associated with FCR is in need of more validated stimuli (pictures and words) 
capturing this specific type of threat (chapter 3). Patients’ qualitative reports of their 
thoughts and associations when confronted with triggers might advance the develop-
ment of experimental tasks in this research area. In the process of gathering further 
information on content and manifestations of high FCR, attention should also be paid 
to patient populations with a poor prognosis like pancreatic cancer. For these patients 
existential issues as part of FCR might be more prominent for instance. Since the studies 
in this thesis were focused on patient populations with a relative favorable prognosis, it 
is not possible to generalize findings to patients with worse prognoses. More research 
on differences and similarities in FCR between different stages of prognoses is important 
to cover both the continuum of fear and the continuum of different diagnoses. A second 
issue lacking in the studies described in this thesis is the assessment of comorbidity. 
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Recent studies show relationships between FCR and both physical [53] and psychiatric 
[10] (history of ) comorbidity. Physical comorbid conditions can be accompanied by 
physiological symptoms, which might be interpreted as signs of disease recurrence [53]. 
For psychiatric comorbidity, patients with severe FCR had more often current psychiatric 
disorders than cancer survivors with non-clinical levels of FCR. A trend in the same direc-
tion for past psychiatric disorders was found [10]. Taken these findings into account, it 
seems important for future research to address the issue of comorbidity as it can be 
valuable in the prediction of which patients are more vulnerable to suffer from high 
levels of FCR.
In order to optimize care for patients with high FCR, systematic assessment of FCR 
is desirable. Accompanying discussion with this proposition is whether this systematic 
assessment should take place in routine follow-up care, follow-up by dedicated nurses 
or the general practitioner. In view of the fact that in routine follow-up little time is avail-
able for psychosocial issues and the medical examinations are associated with high FCR, 
it may be feasible to instruct nurse specialists in how to assess FCR and how to refer 
patients who are in need of help. The national and international recognized instrument 
to screen for a variety of psychosocial issues in clinical practice is the Distress Thermom-
eter (DT). In the Dutch context this is most often completed by the patient together with 
nurse specialists. When patients indicate problems with anxiety and a need for help on 
the DT, dedicated nurse specialists should be encouraged to screen for FCR using an 
FCR specific instrument and to explore whether help with FCR is needed. This systematic 
assessment of psychosocial issues can also be useful in the transition from follow-up 
care in the hospital to general practice setting.
Most important is that assessment of FCR will be a systematic part of follow-up, inde-
pendent of the discussion in which setting this follow-up should take place.  
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Since survival of cancer patients has improved significantly the last decennia, more 
attention should be paid to the psychological burden of having been treated for this 
life-threatening disease. This thesis focused on fear of cancer recurrence (FCR) described 
as the ‘fear, worry or concern about cancer returning or progressing’ in three different pa-
tient populations (breast cancer survivors, colorectal cancer survivors, and patients with 
gastrointestinal stromal tumor (GIST)). Chapter 1 provided background on the current 
state of knowledge on FCR. More specifically, different aspects of FCR including defini-
tion, prevalence, assessment, clinical levels, determinants, course, theoretical model and 
interventions were outlined. In order to detect those patients and survivors for whom 
FCR becomes so overwhelming that it affects quality of life, Chapter 2 described the 
validation of the Cancer Worry Scale (CWS). This study aimed to validate an instrument 
which could accurately differentiate between high and low levels of FCR. Therefore, 
194 female breast cancer survivors filled out questionnaires including the CWS. Results 
showed that a cut-off score of 13 versus 14 (low ≤13, high ≥ 14) on the CWS was optimal 
for differentiating between high and low levels of FCR. A cut-off score of 11 versus 12 
(low ≤ 11, high ≥ 12) was optimal for the purpose of screening. Reliability and validity of 
the CWS were supported indicating that it is a promising instrument to detect elevated 
levels of FCR. Previous studies involving people with anxiety disorders demonstrate an 
attentional bias towards threatening information amongst anxious individuals. To find 
out if it was possible to assess FCR in an implicit way using methods other than self-
report (CWS), an experimental study using the Emotional Stroop Task was conducted in 
Chapter 3. This study investigated whether such a bias exists for cancer-related stimuli 
in breast cancer survivors. Furthermore, it was hypothesized that different levels of FCR 
would lead to different patterns of selective attention. Breast cancer survivors with high 
(n=35) and low (n=32) FCR were compared to 40 healthy female hospital employees. 
Specificity of attentional biases was investigated using a modified Emotional Stroop 
Task including cancer-related words, hospital-related words, positive, negative and 
neutral words. Self-report measures were used to assess depression and anxiety, feel-
ings of fatigue and traumas experienced. Results revealed that compared to control 
participants, breast cancer survivors with both high and low levels of FCR showed 
increased interference for cancer-related words, but not for other word types. These 
findings suggest a specific attentional bias for cancer-related words in breast cancer 
survivors that is independent of level of FCR. Chapter 4 described the study on fear of 
progression in patients with a rare type of cancer called gastrointestinal stromal tumors 
(GIST). GIST’s are rare and before 2000, patients had a dismal prognosis with a median 
survival of less than a year after tumor metastasis. However, the median overall survival 
has increased to more than 5 years following the introduction of imatinib and other 
Chapter 8
126
tyrosine kinase inhibitors (TKI). Little is known about the psychosocial consequences of 
treatment of GIST, but becomes increasingly important due to new treatments accom-
panying prolonged survival. In a cross-sectional design, quality of life, distress, and fear 
of cancer recurrence or progression in patients with GIST was investigated. Eighty-six 
patients with localized or metastatic GIST were asked to participate. Patients completed 
self-report questionnaires including the EORTC-Quality of Life Questionnaire, Hospital 
Anxiety and Depression Scale, Impact of Event Scale, Cancer Worry Scale, and Fear of 
Cancer Recurrence Inventory. Fifty-four patients (median age 63.3 years) completed the 
questionnaires, 33 (61%) of whom were receiving TKI treatment at the time of the study. 
Overall, the GIST patients had a good global quality of life, but 28 patients had high 
levels of fear of cancer recurrence/progression. Interestingly, this high level of fear was 
not related to patient- or treatment-related variables. Patients with elevated levels of 
fear experienced significantly higher levels of psychological distress, functional impair-
ments, and difficulty making plans for the future than did patients with lower levels 
of fear. The main conclusion from this study was that in addition to general quality of 
life issues in patients with GIST, it is also important to pay attention to specific cancer-
related problems such as fear of cancer recurrence/progression since a substantial part 
of patients suffers from high levels of fear. Chapter 5 described an exploratory study 
in colorectal cancer survivors. Although long-term colorectal cancer (CRC) survivors 
generally report a good quality of life, FCR is an important issue. This study investigated 
1) whether the CWS was valid and reliable in a population of colorectal cancer survivors, 
2) the prevalence of FCR, and 3) characteristics and representations of FCR in CRC sur-
vivors. Two hundred and eleven patients who had undergone successful CRC surgery 
in the period 2003 - 2010 in the Radboud University Medical Center in the Netherlands 
were asked to participate. All patients were sent an information letter plus question-
naires for collecting information on demographic and medical variables, FCR, distress, 
and quality of life. Seventy-six patients (36%; median age of 67.7 years; range 41-88 
years) completed the questionnaires a median of 5.1 years after surgery. A cut-off score 
of 14 or higher on the CWS was optimal to detect high FCR. Twenty-nine patients (38%) 
experienced high levels of FCR, characterized by higher levels of distress, post-traumatic 
stress symptoms, and lower quality of life. These individuals particularly reacted to 
disease-related triggers, felt helpless, were worried, and experienced limitations in daily 
functioning. High FCR was not associated with demographic or medical variables. Taken 
together these findings suggest that long after successful CRC surgery, FCR is a serious 
problem that impairs quality of life for a substantial proportion of CRC survivors. Using 
the CWS it is possible to detect high FCR,  and therefore attention should be paid to 
this assessing this specific cancer-related problem amongst CRC survivors in order to 
provide appropriate care. 
127
Summary
Ch
ap
te
r 8
In understanding FCR, it is important to conceptualize it as a multidimensional 
problem in which internal or external cues trigger interpretations and cognitions of the 
threat of cancer, leading to an increase of FCR. This fear may result in dysfunctional be-
haviors, such as limited planning, body checking and seeking professional advice, again 
enhancing an increased fear response. Chapter 6 assessed these relationships in the hy-
pothesized model of FCR. A large sample of breast cancer survivors (n=1205),  who were 
0-5 years after the end of primary breast cancer treatment were invited to participate 
in this study. Participants received a questionnaire booklet including questionnaires on 
demographics and psychosocial variables including FCR. Data analysis consisted of the 
estimation of direct and indirect effects in simple and multiple mediator models. A total 
of 460 women (38%) participated in the study. Median age was 55.8 years (range 32 – 87). 
Indirect effects via FCR were found for all mediation models with limited planning and 
body checking as behavioral response variables, with the largest effects for limited plan-
ning. A direct relation was found between feeling sick and seeking professional advice, 
not mediated by FCR. Different moderators were found for each of the models tested. 
We concluded that in the first tested models of FCR, all internal and external cues were 
associated with higher FCR. In the models with limited planning and body checking as 
behavioral response, an indirect effect of cues via FCR was found. An evidence-based 
model of FCR may facilitate the development of appropriate interventions to manage 
FCR in breast cancer survivors. Chapter 7 contains the discussion of this thesis in which 
the results of the studies were presented into a broader perspective by evaluating their 
merits and shortcomings. Several recommendations for future research were made. 
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De overlevingskansen van patiënten met kanker zijn sterk verbeterd in de afgelopen 
decennia. Daarbij is het belangrijk om meer aandacht te besteden aan de psychosociale 
gevolgen van het zijn behandeld voor deze levensbedreigende ziekte. Dit proefschrift 
richt zich op de angst dat de kanker terugkeert, in het Engels ‘fear of cancer recurrence’ 
genoemd, afgekort als FCR. Deze angst wordt omschreven als de “angst, zorgen of be-
zorgdheid dat de kanker terugkeert of verder uitbreidt”. In drie verschillende patiëntpo-
pulaties (borstkanker, colorectaalkanker en patiënten met gastro-intestinale stromale 
tumor (GIST)) werden studies naar FCR uitgevoerd. hoofdstuk 1 verstrekt achtergrond-
informatie over de huidige stand van kennis over FCR. In dit hoofdstuk werden verschil-
lende aspecten van FCR geschetst zoals de definitie, prevalentie, meetinstrumenten, 
klinische niveaus, determinanten, natuurlijk beloop, theoretisch model en interventies. 
Om patiënten en mensen die verder leven na de behandeling van kanker (survivors) bij 
wie FCR zo overweldigend is dat de kwaliteit van leven beïnvloed wordt te detecteren, 
werd in hoofdstuk 2 een validatiestudie uitgevoerd om te onderzoeken of de Cancer 
Worry Scale (CWS) geschikt was om nauwkeurig onderscheid te maken tussen hoge en 
lage niveaus van FCR. Hiervoor vulden 194 vrouwelijke borstkanker survivors een aantal 
vragenlijsten in waaronder de CWS. De resultaten toonden aan dat een cut-off score van 
13 versus 14 (laag ≤13, hoog ≥ 14) op de CWS optimaal is om het onderscheid tussen 
hoge en lage niveaus van FCR te maken. Een cut-off score van 11 versus 12 (laag ≤ 11, 
hoog ≥ 12) was optimaal voor screening. Betrouwbaarheid en validiteit van de CWS 
werd ondersteund wat aangeeft dat het een veelbelovend instrument is om verhoogde 
FCR detecteren. Om erachter te komen of het naast zelfrapportage (CWS) ook mogelijk 
is om FCR te meten op een onbewuste manier, werd een experimenteel onderzoek met 
de emotionele Stroop taak uitgevoerd in hoofdstuk 3. Eerdere angst studies lieten zien 
dat angstige mensen een aandachtsbias vertonen richting bedreigende informatie. Op 
basis van deze bevindingen werd onderzocht of een dergelijke aandachtsbias bestaat 
voor kanker-gerelateerde stimuli bij borstkanker survivors. Hierbij werd verondersteld 
dat verschillende niveaus van FCR zouden leiden tot verschillende patronen van se-
lectieve aandacht. Borstkanker survivors met een hoge (n = 35) en lage (n = 32) FCR 
werden vergeleken met 40 gezonde vrouwelijke ziekenhuismedewerksters. Specificiteit 
van de aandachtsbias werd onderzocht met behulp van een gemodificeerde Emotio-
nele Stroop Task waarbij gebruik werd gemaakt van kanker gerelateerde woorden, 
ziekenhuis gerelateerde woorden, positieve, negatieve en neutrale woorden. Vragen-
lijsten werden gebruikt om depressie en angst, gevoelens van vermoeidheid en ervaren 
trauma’s in kaart te brengen. Uit de resultaten bleek dat in vergelijking met de gezonde 
ziekenhuismedewerksters, de borstkanker survivors met zowel hoge als lage niveaus 
van FCR meer interferentie toonden voor kanker-gerelateerde woorden, maar niet voor 
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andere categorieën woorden. Deze bevindingen suggereren een specifieke aandachts-
bias voor kanker-gerelateerde woorden bij borstkanker survivors die onafhankelijk is 
van het niveau van FCR. hoofdstuk 4 beschrijft de studie over angst voor progressie 
van kanker bij patiënten met een zeldzame vorm van kanker genaamd gastrointestinale 
stromale tumoren (GIST). GIST’s zijn zeldzaam en vóór het jaar 2000 hadden patiënten 
een sombere prognose met een mediane overleving van minder dan een jaar na de 
tumor metastase. Echter, de gemiddelde algemene overleving is gestegen tot meer dan 
5 jaar na de introductie van imatinib en andere tyrosine kinase inhibitoren (TKI). Er is 
weinig bekend over de psychosociale gevolgen van de behandeling van GIST, maar dit 
wordt steeds belangrijker als gevolg van nieuwe behandelingen die verlengde overle-
ving mogelijk maken. In een cross-sectionele studie werd kwaliteit van leven, FCR, en 
angst voor progressie van kanker bij patiënten met GIST onderzocht. Zesentachtig pa-
tiënten met gelokaliseerde of gemetastaseerde GIST werd gevraagd om deel te nemen. 
Patiënten voltooide zelfrapportage vragenlijsten waaronder de EORTC Kwaliteit van 
Leven vragenlijst, Hospital Anxiety and Depression Scale, Impact of Event Scale, Cancer 
Worry Scale en Fear of Cancer Recurrence Inventory. Vierenvijftig patiënten (gemiddelde 
leeftijd 63,3 jaar) voltooiden de vragenlijsten. Over het geheel genomen vertoonden 
de GIST-patiënten een goede globale kwaliteit van leven, echter 28 patiënten ervoeren 
een hoge mate van angst voor terugkeer of progressie van kanker. Interessant is dat dit 
hoge niveau van angst niet gerelateerd was aan patiënt- of behandeling gerelateerde 
variabelen. Patiënten met een verhoogd niveau van angst ervoeren beduidend hogere 
niveaus van psychische klachten, functionele beperkingen, en hadden meer moeite 
met het maken van plannen voor de toekomst dan patiënten met een lager niveau van 
angst. De belangrijkste conclusie van deze studie was dat naast algemene kwaliteit van 
leven het ook belangrijk is om aandacht te besteden aan specifieke kanker-gerelateerde 
problemen zoals angst voor terugkeer of progressie van de ziekte aangezien een 
aanzienlijk deel van patiënten last hebben van hoge niveaus van angst. hoofdstuk 5 
beschreef een observationele studie bij colorectaalkanker survivors. Hoewel colorec-
taalkanker survivors over het algemeen op de lange termijn een goede kwaliteit van 
leven rapporteren, blijft FCR een belangrijke kwestie. Deze studie onderzocht 1) of de 
Cancer Worry Scale (CWS) ook goede psychometrische eigenschappen had in een po-
pulatie van colorectaalkanker survivors, 2) de prevalentie van FCR, en 3) de kenmerken 
en representaties van FCR in colorectaalkanker survivors. Tweehonderd en elf survivors 
die succesvol geopereerd waren voor colorectaalkanker in de periode 2003-2010 werd 
gevraagd om deel te nemen aan deze studie. Alle deelnemers ontvingen vragenlijsten 
waarin informatie werd verzameld over de demografische en medische variabelen, FCR, 
en de kwaliteit van het leven. Zesenzeventig survivors (36%) voltooiden de vragenlijsten. 
Een cut-off score van 14 of hoger op de CWS bleek optimaal om hoge FCR detecteren. 
Negenentwintig survivors (38%) hadden hoge FCR, gekenmerkt door hogere niveaus 
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van angst, posttraumatische stress-symptomen en een lagere kwaliteit van leven. Deze 
personen reageerden met name op ziekte-gerelateerde triggers, voelde zich hulpeloos, 
waren bezorgd, en ervoeren beperkingen in het dagelijks functioneren. Hoge FCR was 
niet geassocieerd met demografische of medische variabelen. Uit deze studie bleek 
dat zelfs een aantal jaren na een succesvolle operatie voor colorectaalkanker FCR een 
ernstig probleem is dat invloed heeft op de kwaliteit van leven in een aanzienlijk deel 
van de survivors. Met de CWS is het mogelijk om een  hoge FCR detecteren en aandacht 
moet worden besteed aan dit specifieke kanker-gerelateerde probleem om de juiste 
zorg te bieden voor survivors.
Om FCR te begrijpen is het belangrijk om het conceptualiseren als een multidimen-
sionaal probleem waarbij interne of externe stimuli bepaalde cognities en emoties trig-
geren die kunnen leiden tot een toename van angst. Deze angst kan vervolgens weer 
leiden tot disfunctioneel gedrag, (zoals moeite hebben met het maken van plannen voor 
de toekomst, het lichaam controleren op mogelijke symptomen en het consulteren van 
professioneel advies), hetgeen opnieuw een verhoogde angstreactie versterkt. hoofd-
stuk 6 onderzocht deze relaties in het veronderstelde theoretische model van FCR. 1205 
borstkanker survivors, 0-5 jaar na het einde van de primaire behandeling van borstkan-
ker werden uitgenodigd om deel te nemen aan deze studie. Deelnemers ontvingen 
een vragenlijst boekje met daarin vragenlijsten over demografische en psychosociale 
variabelen, zoals FCR. In totaal namen 460 vrouwen (38%) deel aan het onderzoek. De 
mediane leeftijd was 55,8 jaar (32-87). Indirecte effecten via FCR werden gevonden voor 
alle modellen waarin moeite met planning voor de toekomst en het controleren van 
het lichaam als gedragsmatige variabelen werden genomen. Een directe relatie werd 
gevonden tussen ziek zijn en het consulteren van professioneel advies. We concludeer-
den dat in deze studie, waarin voor het eerst de theoretische modellen van FCR uit de 
literatuur getest werden, dat bijna alle interne en externe triggers geassocieerd waren 
met een hogere FCR. In de modellen waarin moeite met het maken van plannen en 
het controleren van het lichaam als gedragsmatige consequenties werden genomen, 
werd een indirect effect van triggers via FCR gevonden. hoofdstuk 7 bestaat uit de 
discussie van dit proefschrift en plaatst de resultaten van de studies in een breder per-
spectief. Daarnaast werd een aantal aanbevelingen voor toekomstig onderzoek gedaan. 
Zo zou eerst duidelijker moeten worden wat ernstige angst voor terugkeer van kanker 
kenmerkt. Vandaar uit kan gewerkt worden aan het bepalen van de meest geschikte 
afkappunten in vragenlijsten om mensen die risico lopen op verhoogde angst te detec-
teren. Dit kan vervolgens gebruikt worden om als startpunt van zorg FCR systematisch 
in kaart te brengen in de klinische praktijk. Inmiddels is op basis van de resultaten in 
dit proefschrift een psychologische behandeling voor ernstige FCR ontwikkeld op de 
afdeling Medische Psychologie van het Radboudumc.
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2014-2015 2.0
  
totAl 56.85
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Graag wil ik een aantal mensen bedanken die betrokken zijn geweest bij de totstandko-
ming van dit proefschrift.
Veel dank gaat uit naar alle patiënten die zich belangeloos hebben ingezet voor de 
verschillende studies beschreven in dit proefschrift. Het invullen van vele vragenlijsten 
en bezoekjes aan het Radboudumc voor het uitvoeren van computertaken hebben dit 
proefschrift mogelijk gemaakt. 
Daarbij aansluitend wil ik graag alle artsen (mw. Hansson, mw. Meersman, mw. Tudyka, 
mw. van Dalsen, mw. Smilde, mw. Honkoop, dhr. Wegdam, dhr. van Berlo, dhr. Leijtens, 
dhr. van Duijvendijk, dhr. van Spronsen) en (regie)verpleegkundigen/casemanagers 
(Marjolein, Jacques, Karin, Hilde, Crisja, Suzanne, Mirjam, Francis, Ivonne, Esther, Erna, 
Ansje, Corinne, Dominique, Hendrien, José, Patricia, Miranda, Franka en Harold) bedan-
ken die de studies onder de aandacht brachten van de patiënten. Het was een ware uit-
daging om de logistiek in de verschillende ziekenhuizen soepel te laten verlopen maar 
ik werd overal hartelijk ontvangen en heb veel bewondering voor de manier waarop 
jullie deze studies oppakten naast de dagelijkse patiëntenzorgtaken. Jullie interesse 
voor de studies en vooral het vermogen om het belang van dit onderzoek uit te leggen 
op vaak lastige momenten in een ziektetraject hebben ervoor gezorgd dat de inclusies 
vlot verliepen en projecten tot een goed einde gebracht werden binnen de gestelde tijd.
Een speciaal woord van dank gaat uit naar mijn promotieteam: Judith Prins, Hans de 
Wilt, Winette van der Graaf en Marieke Gielissen.
Beste Judith, ik herinner me hoe nerveus ik was toen ik voor het eerst bij je aanklopte 
om over mijn onderzoeksvoorstel voor een stage te praten. Je enthousiasme over het 
onderwerp en open houding om ook van mij te willen leren hebben me enorm aange-
moedigd en enthousiast gemaakt over het doen van onderzoek in de medische setting. 
Ik ben je zeer dankbaar voor deze stage, het vertrouwen om me daarna aan te nemen 
als PhD-student, en de kansen die je me daarin geboden hebt om mezelf te ontwikkelen 
zowel op onderzoeksgebied als op persoonlijk vlak. Je blijft me steeds weer aanmoedi-
gen een stap extra te zetten. Ik hoop ook in de toekomst nog samen te blijven werken 
aan onze gezamenlijke ‘onbewuste’ onderzoeksnieuwsgierigheid. 
Beste Hans, jouw belangstelling voor het psychosociaal welbevinden van patiënten 
met darmkanker stond aan de basis van de onderzoeksaanvraag bij fonds NutsOhra. 
Bedankt voor je klinische blik op onderzoeksresultaten en het aanscherpen van discus-
sies. Ik heb onze samenwerking als zeer efficiënt ervaren.
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Beste Winette, jij werd pas later toegevoegd als promotor maar maakte het team 
compleet. Jouw bijdrage als voorzitter van het onderzoeksconsortium zorgde voor een 
inclusie in recordtijd. Je enorme toewijding voor het psychosociale aspect binnen de 
oncologie is aanstekelijk en je kritische reviews van papers vanuit een klinische visie 
zeer waardevol. 
Beste Marieke, als dagelijkse begeleider leerde je me de mores van het onderzoek 
doen op Medische Psychologie. Hoogtepunten werden samen gevierd en wanneer het 
even tegen zat kon ik mijn hart bij jou luchten. We kregen meermaals te horen dat we 
op elkaar lijken en daar ben ik stiekem best trots op! Ik kijk uit naar onze volgende borrel 
bij ‘Eten & Drinken’. 
Ik dank de leden van de manuscriptcommissie prof. dr. A.E.M. Speckens, prof. dr. N. 
Hoogerbrugge en prof. dr. J.A. Roukema voor het beoordelen van dit proefschrift.
Co-auteurs, hartelijk dank voor het meedenken en geven van feedback gedurende het 
schrijfproces van de verschillende artikelen. Eni en Mike, jullie maakten me enthousiast 
tijdens de Research Master voor de wereld van impliciete processen. Ik hoop ook in de 
toekomst hieraan samen verder te kunnen werken. Ook een woord van dank aan Rogier 
en William voor de statistische ondersteuning, aan Rosalie voor de data-invoer van 
enorme stapels vragenlijsten, en aan Michiel en Hanneke voor de hulp bij datamanage-
ment en RadQuest. Belinda, thanks for editing the manuscript and all the help I received 
from you with the completion of this thesis.
Chris, bedankt dat je me de ruimte gaf mijn proefschrift af te ronden. Ik heb ontzet-
tend veel zin om de komende jaren samen de onderzoekslijn bij de sectie ‘kinderen en 
jeugdigen’ door te ontwikkelen.
Alle collega’s van de afdeling Medische Psychologie bedankt voor de goede werksfeer 
waardoor ik elke dag goedgemutst richting het Radboud vertrek.
Collega’s van de onderzoeksgroep ‘psychosociale oncologie’, dankzij jullie werden de 
Journal Clubs, Gammaraden en congresbezoeken leerzame en gezellige bijeenkomsten. 
Mede-challengers, ik heb genoten van ons Da Vinci avontuur!
Emiel, Sanne, Marieke, Annemiek, Eelke, Marloes en Simone, wat een feest om met jullie 
de onderzoekerskamer te mogen delen. Dank voor de discussies, publicatievreugde, kof-
fiemomentjes, themalunches, hardlooprondjes en het delen van onderzoeksperikelen. 
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We blijven elkaar zeker zien en in navolging van Annemiek zie ik jullie sowieso @51°50’ 
14.9”N 5°52’45.2”E, 22-3-2025, 6PM.
Kim, wat leuk dat wij vanaf nu samen een kamer delen!
Sanne, vanaf mijn eerste stagedag nam jij me onder je vleugels en bracht je me groot 
in de wereld van onderzoek. Niet alleen gaf je ontelbare praktische tips maar je verstaat 
ook de kunst om met enkele gerichte vragen me nieuwe inzichten te verschaffen waar-
uit ik weer energie en inspiratie kan putten. Dank daarvoor! Ik ben blij dat je bij mijn 
verdediging als paranimf ook nog een beetje over me hoedt. 
Marloes en Simone, als drie musketiers begonnen we ons promotietraject in 2011. Door 
de gezellige koffiekwartiertjes kregen motivatiedipjes weinig kans. Na vijf jaar zit ons 
gezamenlijk avontuur bij MP erop maar ik ben vol vertrouwen dat onze vriendschap 
zich blijft voortzetten onder het genot van een hapje en balletvoorstelling. Fijn dat jullie 
naast me staan als paranimfen.
Jorrit, ontzettend bedankt voor het super mooie coverdesign!
Lieve schoonfamilie en vriendinnen, bedankt voor jullie interesse, luisterend oor en de 
welkome afleiding in de vorm van gezellig samen eten, thee leuten en weekendjes weg.
Bart, Jantine, Coen en Lian, ook al begrijpen we niet altijd alles van elkaars vakgebied, 
het is hoe dan ook altijd gezellig als we samen zijn. Ik ben blij met jullie en zie uit naar 
een volgend brussenweekend!
Lieve pap en mam, jullie steunen me altijd in de keuzes die ik maak. Bedankt dat we 
altijd aan kunnen kloppen voor praktische en emotionele steun of om gewoon lekker te 
genieten van de rust op het ‘platteland’. 
Lieve Wouter, bedankt voor je interesse, humor en vermogen te relativeren. Maar bo-
venal dank dat het elke dag een feestje is om thuis te zijn met onze lieve Mette. Ik ben 
trots op je!
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José Custers werd op 24 oktober 1987 geboren te Weert. In 2006 behaalde zij het Gymna-
sium diploma aan de Philips van Horne Scholengemeenschap te Weert. Na het afronden 
van de bachelor pedagogische wetenschappen aan de Radboud Universiteit Nijmegen, 
volgde zij de tweejarige Research Master ‘Behavioral Science’ waarin zij onderzoek deed 
bij de afdeling Medische Psychologie van het Radboudumc naar onbewuste processen 
in relatie tot angst voor terugkeer van kanker bij vrouwen die borstkanker hebben 
gehad. In september 2011 kon zij het onderzoek naar deze angst voortzetten als pro-
motieonderzoek, wat leidde tot dit proefschrift. Tijdens haar promotietraject nam José 
deel aan de Radboud Da Vinci Challenge, een programma voor excellente promovendi 
en post-docs gericht op een brede persoonlijke ontwikkeling. Momenteel werkt zij als 
post-doc binnen de sectie ‘Kinderen en Jeugdigen’ van de afdeling Medische Psycholo-
gie waarin zij onderzoek doet naar kwaliteit van leven bij kinderen met een aangeboren 
zeldzame ziekte. José woont samen met Wouter en hun dochter Mette in Nijmegen. 
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“In a sense, a person never really ‘gets over’ cancer:  
it is a sword of Damocles that continues to hang over the individual  
and his or her family for the rest of the person’s life” 
  Muzzin et al., 1994  
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